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Abstract                                   S Maikoo 
Abstract 
The discovery of novel ruthenium metallopharmaceuticals is highly dependent on its 
coordination chemistry. As emphasized in Chapter 1, the biodistribution pathway of 
a potential ruthenium metallopharmaceutical depends on its oxidation state, aqueous 
solubility and the size of its metallic core.  Recent developments are geared towards 
the utilization of biocompatible ligands which may facilitate biodistribution and fine-
tune solubility in the blood stream of the formulated ruthenium anticancer agents. 
This design approach has motivated us to explore the coordination behaviour of 
multidentate N-donor ligands incorporating various biologically active components 
(viz. uracil, antipyrine, chromone or benz(imidazole/othiazole) moieties) towards the 
diamagnetic ruthenium(II) core. The resultant ruthenium compounds were 
characterized via various spectroscopic techniques and structural elucidations were 
confirmed using single X-ray analysis. The structural elucidations were 
complemented with electro-analytical and DFT studies.  
  
In Chapter 3, the coordination reactions of trans-[RuIICl2(PPh3)3] with Schiff bases 
derived from 5,6-diamino-1,3-dimethyl uracil (H2ddd) are reported. In the 
diamagnetic ruthenium(II) complexes, trans-[RuCl(PPh3)2(Htdp)](1)  {H2tdp = 5-
((thiophen-3-yl)methyleneamino)-6-amino-1,3-dimethyluracil} and trans-
[RuCl(PPh3)2(Hsdp)](2) {H2sdp = 5-(2-(methylthio)benzylideneamino)-6-amino-1,3-
dimethyluracil}, the Schiff base ligands (i.e. Htdp and Hsdp) act as monoanionic  
tridentate chelators. Similarly, the diimine H3ucp chelator coordinated as a 
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monoanionic tridentate moiety in complex 3, [RuIICl(PPh3)(H3ucp)] (H4ucp = 2,6-bis-
((6-amino-1,3-dimethyluracilimino)methylene)pyridine). Upon reacting 5-(2-
hydroxybenzylideneamino)-6-amino-1,3-dimethyluracil (H3hdp) with the metal 
precursor, the paramagnetic complex, trans-[RuIVCl2(ddd)(PPh3)2](4) was isolated, in 
which the bidentate dianionic ddd co-ligand was formed by hydrolysis. The presence 
of the paramagnetic metal centre for 4 was confirmed by ESR spectroscopy. DFT 
studies of complex 3 were conducted to provide insight into its intrinsic solid state 
structural features. The redox properties were probed via cyclic voltammetry: 
complexes 1, 2 and 4 exhibited comparable electrochemical behaviour with half-wave 
potentials (E½) at 0.70 V (for 1), 0.725 V (for 2) and 0.68 V (for 4) vs Ag|AgCl 
respectively while the attained half-wave potential (0.37 V vs Ag|AgCl) of 3 was 
significantly lower.   
 
Chapter 4 focuses on the isolation of novel ruthenium(II/III) compounds from the 
respective reactions of the metal precursor, trans-[RuCl2(PPh3)3] with multidentate 
Schiff base ligands bearing the chromone and antipyrine moieties. From these 
coordination reactions of trans-[RuCl2(PPh3)3] with 4-((pyridine-2-
ylimino)methylene)-chromone (pch) and 2,6-bis-((antipyrine-
imino)methylene)pyridine (bpap); the ruthenium(II/III) complexes: trans-P, cis-Cl-
[RuIII(pch)Cl2(PPh3)2] (1) and cis-[RuCl2(bpap)(PPh3)] (2) were formed, respectively. 
The presence of the paramagnetic metal centre of 1 was confirmed via room 
temperature solution ESR spectroscopy. The more delocalized nature of the diimine 
chelator of 2 promotes faster electron transfer resulting in a lower redox potential in 
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contrast to the mono-imine chelator of 1. The electronic spectra of the metallic 
compounds exhibited common intraligand π-π* and red-shifted Metal-to-Ligand- 
Charge-Transfer electronic transitions whilst a d-d electronic transition was only 
observed for the paramagnetic compound 1.  
 
In Chapter 5, the analogous chelating behaviour of bidentate N,O-donor heterocyclic 
ligands which coordinated in a ‘2+2’ coordination mode, is described. The 1:2 molar 
ratio reactions of trans-[RuCl2(PPh3)3] with 2-hydroxyphenylbenzimidazole (Hobz) 
and 2-hydroxyphenylbenzothiazole (Hobs), respectively led to the formation of the 
diamagnetic ruthenium(II) complex salt, [RuCl(Hobz)2(PPh3)]Cl (1) as well as the 
paramagnetic ruthenium complex, [RuIIICl(obs)2(PPh3)] (2). The X-ray crystal 
structures of both metallic compounds confers a distorted octahedral geometry 
imposed by the mutual ’2+2’ coordination modes of the chelators. DFT studies 
indicated that the complex cation of 1 was more energetically favourable than the 
neutral complex 2. Solid state ESR analysis of the paramagnetic complex 2 gave rise 
to a distorted rhombic spectra whilst the liquid state ESR afforded an isotropic singlet 
(at 298 K) and three distinctive signals (at 77 K). 
 
Keywords: Ruthenium (II/III/IV); Schiff base ligands; Electron Spin Resonance (ESR); 
Voltammetric analysis; Density functional Theory (DFT); Chromone; Antipyrine; 






Preface           S Maikoo 
Preface 
The experimental work in this dissertation was carried out in the School of Chemistry 
and Physics, University of KwaZulu-Natal, Pietermaritzburg, from January 2013 to 
March 2014, under the supervision of Doctor Irvin N. Booysen. 
 
These studies represent original work by the author and have not otherwise been 
submitted in any form for any other degree or diploma to any tertiary institution. 





Declaration 1          S Maikoo 
Declaration 1 – Plagiarism 
I, Sanam Maikoo, declare that: 
 
1. The research reported in this dissertation, except where otherwise indicated, is 
my original research. 
 
2. This dissertation has not been submitted for any degree or examination at any 
other university.  
 
3. This dissertation does not contain any other persons’ data, pictures, graphs or 
other information, unless specifically acknowledged as being sourced from 
other persons’. 
 
4. This dissertation does not contain any other persons’ writing, unless 
specifically acknowledged as being sourced from other researchers. Where 
other written sources have been quoted, then: 
a. Their words have been re-written but the general information attributed to 
them has been referenced. 
b. Where their exact words have been used, then their writing has been placed 
in italics and inside quotation marks, and referenced. 
 
5. This dissertation does not contain text, graphics or tables copied and pasted 
from the internet, unless specifically acknowledged, and the source being 







Declaration 2          S Maikoo 
Declaration 2 – Publications 
Manuscripts Published 
 Booysen, I.N., Maikoo, S., Akerman, M.P., Xulu, B., Munro, O. 
“Ruthenium(II/IV) complexes with potentially tridentate Schiff base chelates 
containing the uracil moiety.” J. Coord. Chem., 2013, 66, 3673. 
 Booysen, I.N., Maikoo, S., Akerman, M.P., Xulu, B. “Novel Ruthenium(II) and 
(III) compounds with Multidentate Schiff base chelates bearing biologically 
significant moieties.” Polyhedron, 2014, in press, 
http://dx.doi.org/10.1016/j.poly.2014.05.021. 
In Preparation 
 Booysen, I.N., Maikoo, S., Akerman, M.P., Xulu, B. “Isolation of ruthenium 
compounds from the analogous chelating behaviour of 2-
hydroxyphenylbenz(imidazole/othiazole).” Trans. Met. Chem., 2014. 
 
The formulated compounds in the aforementioned manuscripts have been 
synthesized, characterized and analysed by myself. For publication 1, single crystal 
samples were run and solved by Prof. O. Munro and Dr M. Akerman. The ESR 
spectrum was run by Dr B. Xulu and the paper was written by Dr I. Booysen for 
publication. For the manuscript submitted for review, single crystal samples were run 
and solved by Dr M. Akerman. The ESR spectrum was run by Dr B. Xulu. Dr I. 
Booysen, wrote the paper for submission. The article currently in preparation is being 
written by Dr I. Booysen. The single crystal XRD samples were run and solved by Dr 





Signed: _______________      Signed: ______________ 
Sanam Maikoo       Dr I.N. Booysen 
 
Signed: _______________      Signed: ______________ 
Prof. O.Q. Munro       Dr M.P. Akerman 
 
Signed: _______________       







Acknowledgements                                  S Maikoo 
Acknowledgements 
I would like to express my first debt of gratitude to my supervisor, Dr. Irvin N. 
Booysen for his never ending patience, the countless hours of his time as well as the 
fine balance of intellectual support and guidance that he has provided to me during 
this study.   
 
Furthermore, I would also like to express my appreciation to our research group, M. 
Ismail, T. Hlela, A. Adebisi and S. Chohan as well as my other chemistry colleagues 
and friends, S. Seunarian, S. Bhikraj, L. Hunter, L. Dralle, V. Chiazzari and T. Zacca 
for their help and support. 
 
In addition, I am grateful to Prof. O.Q. Munro and Dr. M.P Akerman for running our 
single crystal X-ray crystallographic samples and to Dr. B.X. Xulu for attaining our 
raw Electron Spin Resonance data. 
 
My studies would not have been conceivable without my mum, Prema Maikoo. In 
particular, her love, support and many sacrifices she has made for me. I would also 
like to thank my father, Subhash Maikoo, for his encouragement and support. 
 
I am thankful towards the University of KwaZulu-Natal for providing me with the 
laboratory and equipment required for this study. 
 
Lastly, but most importantly, I am highly grateful to God for the courage and strength 





Crystallographic Data                      S Maikoo 
Crystallographic Data 
Supplementary data for all the crystal structures obtained during this study are stored 
on a compact disk that is attached to the inside back cover of this dissertation. 
 
This data includes the following: 
 
 Final coordinates and equivalent isotropic displacement parameters of the non-
hydrogen atoms; 
 Final crystal data and details of the structure determinations; 
 Isotropic displacement parameters; 
 Hydrogen atom positions; 
 Contact distances; 
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Chapter 1 
Introduction 
1.1 General Background 
 
Ruthenium is a 4d element with an atomic number of 44. This rare transition metal is 
the 74th most abundant element on earth and occurs naturally in the ores of the 
platinum group metals, e.g. pyroxenite in South Africa. Seven natural occurring 
isotopes (viz.96, 98-104Ru) are known while several radioisotopes have been discovered 
with atomic masses ranging from 87 to 124 [1, 2]. Furthermore, this metal [Kr4d75s1] 
exhibits variable oxidation states ranging from 0 to +8 by utilizing its valence d- and 
s-electrons but can also extend into its krypton core attaining the -2 oxidation state, 
e.g. [Ru(CO)4]2- [3]. Characteristic to most d-block elements, the acidic cores of 
ruthenium are commonly stabilized by N3- and O2- moieties while lower oxidation 
states are stabilized by strong pi-back bonding ligands like the carbonyls [4]. 
 
Numerous ruthenium complexes with N-donor heterocyclic chelators have been 
isolated due to the metal centre’s characteristic affinity for neutral nitrogen donor 
atoms (e.g. pyridyl). Most recently, the discovery of NAMI-A, trans-
[RuCl4(DMSO)(Im)](ImH) {ImH = imidazole}  as a potential metallopharmaceutical 
for metastatic cancer, has led to a renewed interest into the medicinal inorganic 
chemistry of ruthenium [5]. In addition, as a result of the emergence of ruthenium 
radiochemistry, the radio-therapeutic applications of the 106Ru radionuclide have been 
widely investigated due to its optimal half-life (371.8 days) and β-max energy [3, 6]. 
 
Beside these promising medicinal applications, the rich organometallic chemistry of 
ruthenium coupled with its easily accessible oxidation states have afforded metal 
complexes with profound catalytic properties [7, 8]. This class of metal complexes is 
readily stabilized by either aliphatic (e.g. allyl) or aromatic (e.g. arene) carbon-based 
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cores [8, 9].  The most prominent of them all, is the Grubbs catalysts which are the 
most widely utilized organoruthenium catalyst in olefin metathesis [10]. 
 
1.2 Aim and Motivation 
 
In the last decade, there has been a growing interest in the development of new 
ruthenium metallopharmaceuticals due to the discovery of NAMI-A, trans-
[RuCl4(DMSO)(Im)](ImH) {Im = imidazole}. NAMI-A has recently entered Phase II 
clinical trials due to its excellent metastatic cancer activity which is accompanied with 
fewer significant side effects than platinum-based metallopharmaceuticals [11]. 
Recent developments are geared towards the utilization of biocompatible ligands 
which may facilitate biodistribution and fine-tune solubility in the blood stream of the 
formulated ruthenium anticancer agents [12, 13]. This design approach has motivated 
us to explore the coordination behaviour of multidentate Schiff base ligands 
(incorporating biologically relevant moieties) as well as benz(othiazole/imidazole)-
derived chelators (see Figure 1.1) towards the RuII/III cores. In particular, Schiff bases 
derived from 3-formylchromone, 4-aminoantipyrine and 5,6-diamino-1,3-





X = NH (Hbz)
    = S (Hbs)  
Figure 1.1: Generic structure of the heterocyclic ligands: 2-hydroxyphenyl-1H-
































Figure 1.2: Structures of 4-((pyridine-2-ylimino)methylene)-chromone (pch), 2,6-bis-((6-
amino-1, 3-dimethyluracilimino)methylene)pyridine (H4ucp) and 2,6-bis-((antipyrine-

























Figure 1.3: Structures of 5-((thiophen-3-yl)methyleneamino)-6-amino-1,3-dimethyluracil 
(H2tdp), 5-(2-(methylthio)benzylideneamino)-6-amino-1,3-dimethyluracil (H2sdp) and 5-(2-
hydroxybenzylideneamino)-6-amino-1,3-dimethyluracil (H3hdp). 
 
Schiff bases are known to stabilize ruthenium in the oxidation states +II and +III which 
is emphasized by the metal center’s preferential coordination affinity towards neutral 
nitrogen donor atoms, like imino and pyridyl nitrogens [14, 15]. Furthermore, the 
utilization of multidentate Schiff base ligands renders additional thermodynamic 
stability through the formation of chelate rings [16]. These organic molecules can also 
be readily synthesized by condensation reactions in either organic media or via 
solvent-free methods [17]. In addition, derivatization of Schiff bases allows for the 
incorporation of biomolecules and functionalization allows for manipulation of 
solubility in aqueous or organic media [18]. Due to the above reasons, many transition 
metal complexes have shown inherent and enhanced biological activities with respect 
to their free Schiff base ligands [19]. 
 
In particular, Schiff bases derived from 4-aminoantipyrine and their ruthenium 
complexes have shown an array of biological activities including antioxidant, 
antibacterial and anti-oxidant activities as well as DNA binding capability [20]. Like 
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in the case of the organometallic ruthenium(II) complex, [RuCl(CO)(B)(oap)] (Hoap = 
4-((2-hydroxybenzylidene)imino)-aminoantipyrine, B = PPh3/AsPh3/py) containing 
the monoanionic OketoNiminoO tridentate oap chelator, showed optimal DNA cleavage 
activity [21]. Our selection of the chromone moiety is based on its biological relevance 
as a secondary metabolite. In addition, chromone Schiff base transition metals 
complexes have shown to exhibit excellent anti-tumour behaviour [22]. The 
motivation behind the use of 5,6-diamino-1,3-dimethyluracil is its biological relevance 
as a nucleotide base derivative as well as the fact that uracil-derivatives are well 















Figure 1.4: Structures of 5,6-diamino-1,3-dimethyluracil (H2ddd) and uracil mustard. 
 
Ruthenium complexes containing 2-pyridylbenz(imidazole/othiazole)-derived 
ligands have been widely investigated due to their excellent 
electrochemiluminescence (ECL) properties [24]. Indicative to the ruthenium Schiff 
base compounds, ruthenium complexes with these N-donor heterocyclic chelators 
have been found to exhibit numerous pharmacological activities such as anticancer, 
antifungal and antimicrobial properties [25]. The combinations of these ECL and 
biological properties have proven useful in the advancement towards new ruthenium 
diagnostic agents. For example, the DNA binding modes of a number of 
benzothiazole-substituted tris-bipyridine ruthenium(II) analogues were investigated 




In this study, X-ray analysis indicated that the mono-imine and the highly delocalized 
diimine ligands afforded either bidentate, tridentate or tetradentate chelators whilst 
the heterocyclic ligands coordinated in a ‘2+2’ manner to the ruthenium metal centre. 
The formulated ruthenium complexes showed comparable geometrical parameters as 
other ruthenium complexes found in the literature [27, 28].  
 
1.3 Schiff Bases and Benz(imidazole/othiazole) Compounds 
 
Schiff bases and benz(imidazole/othiazole) compounds are intriguing organic 
constituents which both contain sp2-hybrydized carbon to nitrogen (C=N) double 
bonds where in Schiff bases the characteristic functional group is an aliphatic bridge 
R-C=N-R’ while the C=N bonds of the benz(imidazole/othiazole) compounds forms 
part of constrained five-membered chelate rings, see Figure 1.5 [14, 29, 30]. 
Derivatization and functionalization of their general structures have led to unique 
structure-activity relationships [31]. For this reason, Schiff bases with a wide range of 
biological activities have been isolated and benz(imidazole/othiazole) moieties are 







X = S (Benzothiazole) 
or NH (Benzimidazole)
R or/and R' = aliphatic or aromatic groups
 
Figure 1.5: General structures of Schiff bases and benz(imidazole/othiazole) compounds. 
 
Among the numerous examples is 2-dodecyloxy(benzylidene)-acetic acid which 
displays significant antitumor activity against a wide range of cell lines [34]. In 
addition, Riluzole (6‐trifluoromethoxy‐2‐benzothiazolamine, (see Figure 1.6) is a drug 
used to treat lateral sclerosis as it was found to hinder glutamate neurotransmission 
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during electrophysiological and biochemical behavioural experiments [35]. Another 
example is the benzothiazole-derived radiopharmaceutical, Pittsburgh Compound B 
(see Figure 1.7) which is used for the diagnosis of amyloidal plaques in the brain 
which is the primary cause of Alzheimer’s disease [36].  Organic compounds 
containing benzimidazole moieties have also illustrated profound biological activities, 
like in the case of 4-(5,6-dimethyl-1H-benzimidazol-2-yl)benzene-1,3-diol which was 
found to display antiproliferative activity against the human bladder cancer cell lines, 


































Figure 1.7: Structures of Pittsburgh compound B (A) and 4-(5,6-Dimethyl-1H-
benzimidazol-2-yl)benzene-1,3-diol (B). 
 
Schiff bases and benz(imidazole/othiazole) compounds typically show higher 
biological activities upon coordination since the resultant metal complexes have 
shown stronger in vivo interactions via covalent or ionic bonding and also combines 
the unique stereo-electronic properties of their chelators for interactions with 
biological targets. Thus the increased activity is ascribed to stronger covalent 
interactions between the metal and the donor atoms of the biological target molecule. 
In addition, the metal is able to position the ligands in appropriate positions so that 
optimal interactions may occur between the biological target and the ligands. This 
metal-ligand synergistic relationship has been observed in numerous examples, e.g. 
complexes of M(II) {M = Ni, Co, Zn and Cu} containing a Schiff base (derived from 3-
ethoxy-salicylaldehyde and 2-aminobenzoic acid) showed an increase in antibacterial 
activity compared to their free ligands [38, 39]. Also, the interaction of the copper(II) 
compound, Cu(bzap)(ClO4)2 (bzap = N,N,N’,N’-tetrakis[(2-benzimidazolyl)methyl]-
1,3-diaminopropane) with DNA was investigated and it was found that the complex 
is able to bind to the phosphate backbone of the DNA backbone and partially 
intercalate into the double helix due to the planarity of the highly conjugated, 




1.4 Ruthenium Metallopharmaceuticals 
 
Cisplatin, cis-[Pt(NH3)2Cl2] (see Figure 1.8) was the very first metal-based anticancer 
drug approved by the FDA in 1978 [41]. This metallo-drug destroys tumour cells via 
the interference of transcription and replication processes which subsequently 
triggers apoptosis [42]. However, there are numerous side effects that accompany the 
use of cisplatin and this could be attributed to the fact that it does not specifically 
target tumour cells but also targets other healthy cells in the body, such as, the rapidly 
dividing cells of the gastrointestinal tract, the hair follicles and bone marrow. This 
causes numerous side-effects like hair loss and nausea and in addition the 
development of drug resistance in tumour cells may occur [43]. Therefore, cancer 
treatment with the use of metal-based anticancer drugs requires selectivity for 







Figure 1.8: Structure of Cisplatin. 
 
In comparison to platinum-based anticancer drugs, there are numerous traits of 
ruthenium compounds which make them promising for the design of novel 
antitumour drugs. Literature studies have shown that ruthenium anticancer drugs 
show antimetastatic activity (i.e. prevention of the spreading of cancer cells to other 
tissues or organs) in cells that have previously developed a resistance to cisplatin. 
These anticancer ruthenium-based drugs adopt biological mechanisms of activities 
which are highly dependent on their respective oxidation states. For example, selected 
ruthenium(III) complexes have been classified as pro-drugs which are activated 
through ‘activation by reduction’ theory. This reduction phenomenon induces more 
selective toxicity and is thought to be induced by the lower pH and oxygen content 
within tumour cells and by the covalent-binding of low-molecular weight 
biomolecules [44, 45, 46]. This is further supported by the fact that Pt(II) pro-drugs 
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and Ru(III) anticancer compounds have comparative substitution kinetics with 
various biological nucleophiles [47].  
 
Ruthenium(III) complexes have also shown lower toxicity (compared to cisplatin) as 
these metallo-drugs target the cancer cells via transferrin receptors [48]. This is 
ascribed to the mimetic capability of ruthenium to its group congener iron’s binding 
to transferrin, a protein found within mammals. In particular, the leading ruthenium 
anticancer compounds, NAMI-A and indazolium-trans-[tetrachloro-bis(1H-
indazole)ruthenate(III)] (KP1019) are converted to the active Ru(II) species by the 
stepwise dissociation of two chlorides under physiological conditions, see Figure 1.9. 
These active species are able to bind to enzymes and proteins on tumour cell 
membranes and induces apoptosis via the mitochondrial pathway (for KP1019) or by 



























Figure 1.9: The leading candidates for the first ruthenium metallopharmaceuticals:  NAMI-




Furthermore, arene ruthenium(II) complexes have largely acted as Topoisomerase II 
inhibitors whereas octahedral saturated complexes containing the [Ru(bpy)2]2+ core 
have been found to exhibit DNA interchelating activities. In addition, several 
ruthenium-nucleotide base complexes have been isolated which suggest that 
ruthenium complexes can also coordinate preferentially directly on the DNA double 
helix. For example, the organometallic ruthenium(II) complex, [RuCl2(p-cymene)adp] 
(adp = 3-aza-5H-phenanthridin-6-one) have shown several modes of anticancer 
activity via DNA binding facilitated by the monodentate adp moiety as well as 
through inhibition of transcription and Poly(ADP-ribose) polymerase-1 (PARP-1), see 









Figure 1.10: Structure of the metal-based DNA interchelator, [RuCl2(cymene)adp]. 
 
1.5 General Chemistry of Ruthenium(II/ III) 
 
1.5.1 Ligand Substitution 
 
The low-spin ruthenium(II) centre is predominately kinetically inert but ligand 
substitution can be promoted by utilizing metal precursors (e.g. cis-[RuCl2(bpy)], 
trans-[RuCl2(PPh3)3]  and (μ-Cl)2[RuCl(p-cymene)]2 with labile co-ligands within their 
coordination spheres [53]. For example, substitution kinetic studies of the 
ruthenium(II) complexes, [Ru(terpy)(tmen)(OH2)]2+ (terpy = 2,2: 6’,2”-terpyridine, 
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bipy = 2,2’-bipyridine and tmen = N,N,N’,N’-tetramethylethylenediamine) suggests 
that the metal complex bearing the more π-conjugated tmen bidentate chelator aids 
faster ligand exchange of DMTU (1,3-dimethyl-2-thiourea), refer to Equation (1) [54].  
 
[Ru(terpy)(tmen)(OH2)]2+ + DMTU →  [Ru(terpy)(tmen)(DMTU)]2+ + H2O   (1) 
 
Indicative to the aforementioned, the paramagnetic ruthenium(III) complex, 
[Ru(edta)(H2O)] (H3edta =  ethylenediaminetetraacetic acid) undergoes dehydration 
upon the reaction with 2-mercaptophenylcarboxylate (Hmpc); retaining the low-spin 
d5 metal centre in  [Ru(Hedta)(Hmpc)] [55], refer to Equation (2). 
 
[Ru(Hedta)(H2O)] + Hmpc → [Ru(Hedta)(Hmpc)] + H2O     (2) 
 
1.5.2 Redox Reactions 
 
Ruthenium complexes in its oxidation states +II and +III are typically highly redox 
active and therefore are prone to ligand-induced oxidation and reduction reactions. 
This can be seen in Equation (3) in the formation of the ‘2+2’ ruthenium(III) complex, 
[RuIIICl(bsp)2(PPh3)] (Hbsp = N-(2-hydroxybenzylidene)-benzimidazole) from the 
diamagnetic metal precursor, trans-[RuIICl2(PPh3)3] [56]. 
 
trans-[RuIICl2(PPh3)3] + 2Hbsp → [RuIIICl(bsp)2(PPh3)] +2HCl + 2PPh3                (3) 
   
Some ruthenium(III) complexes also have the propensity to be oxidized to its Ru+IV or 
Ru+V species by oxidants such as O2 and H2O2. A typical example is the ruthenium(III) 
polyaminecarboxylato complex [RuIII(edta)(H2O)]– which is oxidized by a reaction 
with H2O2 to produce the [RuV(edta)(O)]– specie which is used in the hydroxylation of 
arginine [57, 58]. Furthermore, ruthenium(II) polypyridyl complexes have a tendency 
to be converted to its excited state by visible light which is subsequently reduced or 
oxidized by appropriate quenching agents. This excited state seems to result from the 
transfer of an electron from the metal t2g orbitals to the ligand π* orbital [59]. For 
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example, during the photocatalytic oxidation of water to produce dimolecular oxygen; 
the excited *[Ru(bipy)3]3+ (bipy = bipyridine) is generated from the  oxidation of 
*[Ru(bipy)3]2+ by an oxidant, S2O82-, refer to Equations (4) and (5)  [60]. 
 
4*[Ru(bipy)3]2+ + 2S2O82- → 4*[Ru(bipy)3]3+ + 4SO42-     (4)  




The disproportionation reactions of ruthenium(II/III) complexes have been 
extensively studied due to the relevance of the products (as oxidants and reductants) 
in organometallic catalysis and in  DNA-oxidation studies [61, 62]. More specifically, 
ruthenium(III) complexes have been known to disproportionate into RuII and RuIV 
species under basic conditions. Taube et al. reported the disproportionation of 
[RuIII(NH3)5(py)] under basic conditions which yielded [RuII(NH3)5(py)] and 
[RuIV(NH3)4(NH2)(py)] [63], refer to Equation (6).  
 
2[Ru(NH3)5(py)]3+ + OH- → [Ru(NH3)5(py)]2+ + [Ru(NH3)4(NH2)(py)]4+ + H2O (6) 
 
Disproportionation for ruthenium(II) complexes are not common but similar to the 
abovementioned example, a very unusual proton-assisted disproportionation, 
involving the complex RuII(NH3)2(bqdi)Cl2 (bqdi = o-benzoquinonediimine), was 
reported by Kapovsky et al. It was observed that the complex, [RuII(NH3)2(bqdi)Cl2] 
(A) undergoes disproportionation, upon exposure to ultraviolet-visible light, forming 
the two final ruthenium(III) species (one reductant and one oxidant), refer to 
Equations (7) and (8). Initially, the intermediate B, [RuIV(NH3)2(opda)Cl2]2+ (opda = 
1,2-phenylenediamine) is formed via the protonation of the diimine nitrogen donors 
of the bqdi moiety. The resultant intermediate (B) induces oxidation of the remaining 
molecules of (A) to afford the paramagnetic complex cations, [RuIII(NH3)2(opda)Cl2]+ 




[RuII(NH3)2(bqdi)Cl2 (A) + 2H+ → [RuIV(NH3)2(opda)Cl2]2+ (B)   (7) 
 
(A) + (B) → [RuIII(NH3)2(opda)Cl2]+ + [RuIII(NH3)2(bqdi)Cl2]+                (8) 
            
1.6 Coordination Chemistry of Ruthenium (II/III) 
 
1.6.1 Ruthenium Compounds with N, N-donor ligands 
 
Ruthenium demonstrates a general affinity towards neutral nitrogen-donor atoms like 
imino and pyridyl nitrogens [64, 65]. Typical examples includes the ruthenium(II) 
compounds [Ru(bbz)Cl(PPh3)]+ (bbz = N,N’-bis(benzimidazol-2yl-
ethyl)ethylendiamine) and trans-[RuCl(trpy)(PPh3)2](PF6) (trpy = 4,4’,4’’-tri-t -butyl-
2,2’:6’,2’’-terpyridine), see Figures 1.11 and 1.12 [66, 67]. However, high and low 
oxidation states of ruthenium are readily stabilized by the deprotonated forms of 
nitrogen-donor atoms (e.g. amido) as these function as good σ-donors [68]. Therefore, 
it comes as no surprise that the majority of ruthenium compounds contain 
















Figure 1.11: Structures of the free bbz ligand and its corresponding complex cation 
















Figure 1.12: Structure of the trans-[RuCl(trpy)(PPh3)2]+ ion and its free trpy ligand which 
acts as a neutral tridentate chelator. 
 
1.6.2 Ruthenium Compounds with N, S-donor ligands 
 
Metal complexes of ruthenium containing nitrogen, sulfur-donor ligands are of 
considerable interest due to their intricate redox and electronic properties which stems 
from their unusual structural features [69, 70]. Sulfur donors can readily exist in 
several hybridized forms and when coordinated to ruthenium; can either be σ-donors 
or can be strong 3dπ back-bonding ligands [71]. This phenomenon can be illustrated in 
the following ruthenium(II) Schiff base complex, trans-[Ru(mpnap)(CO)(PPh3)2] 
(H2mpnap = 1-(2-mercaptophenylimino)methyl)naphthalen-2-ol) where sigma-bond 
donation occurs between from the deprotonated thiol  atom to the metal centre [14], 
see Figure 1.13. In the case of the mononuclear complexes, [Na][trans-
RuIIICl4(DMSO)(L)] and its dimer, [Na]2[{trans-RuIIICl4(DMSO)}2(L)], the neutral 
DMSO coordination bonds are formed via pi-back donation from the metal into the 

















Figure 1.13: The structure of the dianionic, tridentate mpnap moiety and the skeletal 
































Figure 1.14:  The monomeric (A) and dimeric (B) forms of [Na][trans-RuIIICl4(DMSO)(L)]. 
 
1.6.3 Ruthenium Compounds with N, O-donor Ligands 
 
Schiff bases that contain nitrogen and sulfur atoms have attracted much research 
interest due to their versatile electronic and steric properties [73]. Designing Schiff 
base ligands with hard and soft donors have proven favorable in the isolation of 
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numerous ruthenium(II/III) complexes [74, 75]. Some isolated complexes of this 
nature include the monoamine and diimine ruthenium complexes, 
[RuIII(ahsH)(PPh3)2Cl] (H2ahsH = N-(acetyl)-N’-(salicylidene)hydrazines) and  
[RuII(salen)(PPh3)2] containing the N2O and N2O2 donor sets within the equatorial 
plane, respectively as well as for both complexes, being re-enforced by the trans-
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Experimental          S Maikoo 
Chapter 2 
Experimental 
2.1 Handling of Ruthenium 
 
Ruthenium compounds are considered environmentally hazardous, carcinogenic and 
highly toxic. These compounds can potentially form the poisonous and volatile 
ruthenium tetroxide when heated in air that can seriously damage the respiratory 
system and eyes [1]. Therefore, several special precautions were taken into account 
during the handling of all ruthenium compounds including the wearing of latex 
gloves and a dust mask at all times as well as the use of a fume cupboard in which all 




2.2.1 Metal precursor 
The metal precursor, trans-[RuCl2(PPh3)2] (97% purity) was obtained from Sigma-
Aldrich and no further purification was conducted on this chemical. 
 
2.2.2 Commercially acquired chemicals 
All solvents and common laboratory chemicals were of analytical grade and used 
without any further purification. The chemicals listed in Table 2.1 were purchased 









Table 2.1: List of chemicals attained from Sigma-Aldrich. 










2-Hydroxyphenylbenzimidazole (Hobz) 95% 
2-Hydroxyphenylbenzothiazole (Hobs) 97% 
Piperidine 99% 
Ammonium tetrafluoroborate 99% 
 
2.3 Synthetic Procedures of Schiff Base Ligands 
 
2.3.1 Synthesis of 5-((thiophen-3-yl)methyleneamino)-6-amino-1,3-dimethyluracil (H2tdp) 
H2ddd (0.500 g; 2.94 mmol) and thiophene-2-aldehyde (0.399 cm3; 4.41 mmol) were 
refluxed for 3 hours in methanol (40 cm3). The resulting dark yellow solution was 
allowed to cool to room temperature, filtered and a bright yellow precipitate was 
washed with cold anhydrous toluene as well as diethyl ether. Yield = 63%; m.p. 240.7–
242.0 ˚C. IR (νmax/cm-1): ν(N-H) 3396, 3286, ν(C=O) 1671, ν(C=N) 1611, ν(thiophene) 
1506, 1447 and 1380. 1H NMR (295K/d6-DMSO/ppm): 9.79 (s, 1H, H1), 7.58 (d, 1H, 
H4), 7.41 (d, 1H, H2), 7.95 (t, 1H, H3), 6.96 (br, s, 2H, NH2), 3.42 (s, 3H, CH3), 3.18 (s, 


















Figure 2.1: Numbering scheme for H2tdp. 
 
 
Figure 2.2: 1H NMR of the H2tdp ligand in the range of 9.90 – 5.90 ppm. 
 
2.3.2 Syntheses of 5-(2-(methylthio)benzylideneamino)-6-amino-1,3-dimethyluracil 
(H2sdp)  and 5-(2-hydroxybenzylideneamino)-6-amino-1,3-dimethyluracil (H3hdp) 
The Schiff bases, H3hdp and H2sdp were synthesized as previously reported from the 
condensation reactions of H2ddd with 2-methylthiobenzaldehyde and 




2.3.3 Synthesis of 2,6-Bis-((6-amino-1,3-dimethyluracilimino)methylene)pyridine (H4ucp) 
A reaction mixture of 5,6-diamino-1,3-dimethyluracil (1.25 g; 7.40 mmol) and 
pyridine-2,6-dicarbaldehyde (0.503 g; 3.72 mmol) was heated at reflux in methanol (40 
cm3) in the presence of a catalyst,  piperidine (3 drops). After 3 hours, the bright orange 
solution was allowed to cool to room temperature and the yellow precipitate which 
formed was collected (via filtration), washed with cold methanol as well as petroleum 
ether. Yield = 95%, m.p. = 234–237 °C.  IR (νmax/cm-1): ν(C=O) 1678 (s), ν(C=N) 1596 
(s); 1H NMR (295K/ppm, see Fig. S2): 9.70 (s, 2H, H4, H8), 8.33 (d, 2H, H5, H7), 7.78 (t, 
1H, H6), 7.46 (br, s, 4H, N(1)H2, N(11)H2), 3.41 (s, 6H, C3H3, C9H3), 3.19 (s, 6H, C2H3, 
C10H3). UV-Vis (DMF, λmax (ε, M-1cm-1)): 233 nm (7900), 278 nm (sh, 4900), 285 nm 

































Figure 2.4: 1H NMR spectrum of H4ucp in the range of 7.30 - 9.75 ppm. 
 
2.3.4 Synthesis of 4-((pyridine-2ylimino)methylene)-chromone (pch) 
The condensation reaction of 3-formylchromone (0.925 g; 5.31 mmol) and pyridin-2-
amine (0.510 g; 5.42 mmol) was conducted in methanol (30 cm3) under reflux (for 3 
hours) in the presence of three drops of piperidine. The orange solution was allowed 
to cool to room temperature and a mustard-coloured precipitate was filtered and 
washed with cold methanol as well as petroleum ether. Yield = 95%, m.p. = 115 – 118 
°C.  IR (νmax/cm-1): ν(C=O) 1647 (s), ν(C=N) 1611, 1603, 1590 (s), ν(C-O-C) 1557; 1H 
NMR (295K/ppm): 11.77 (d, 1H, H1), 8.40 – 8.34 (m, 4H, H4, H5, H6, H10), 7.89 – 7.70 
(m, 2H, H2, H3), 7.59 – 7.51 (m, 2H, H8, H9), 7.36 (d, 1H, H7). UV-Vis (DMF, λmax (ε, M-

















Figure 2.5: Numbering scheme for pch. 
 
2.3.5 Synthesis of 2,6-bis-((antipyrine-imino)methylene)pyridine (bpap) 
The synthetic procedure of the diimine ligand, 2,6-bis-((antipyrine-




The infrared spectra were recorded on a Perkin-Elmer Spectrum 100 in the 4000– 650 
cm-1 range. The 1H NMR spectra were obtained using Bruker Avance 400 MHz and 
500 MHz spectrometers, respectively. The X-band EPR spectra were obtained from 
Bruker EMX Premium and Ultra X spectrometers. UV/visible spectra were recorded 
using a Perkin Elmer Lambda 25. The extinction coefficients (ε) are given in dm3 mol-
1 cm-1. Melting points were determined using a Stuart SMP3 melting point apparatus. 
The conductivity measurements were determined at 295 K on a Radiometer R21M127 
CDM 230 conductivity and pH meter. A solution of 0.745 g KCl in 1 L of ultrapure 
water was used as the standard solution.  
 
Cyclic voltammetry measurements were done using an Autolab potentiostat 
equipped with a three electrode system: A glassy carbon working electrode (GCWE), 
a pseudo Ag|AgCl reference electrode and an auxiliary Pt counter electrode. The 
Autolab Nova 1.7 software was utilized for the operation of the potentiostat and data 
analysis. The ruthenium metal complexes were made up in 2 mM solutions in DCM 
along with tetrabutylammonium hexafluorophosphate (0.1 M) as a supporting 
electrolyte. Between each measurement, the GCWE surface was polished with slurry 
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of ultrapure water and alumina on a Buehler felt pad followed by rinsing with excess 
ultrapure water and ultra-sonication in absolute ethanol. Ultrapure water was 
produced from an ElgaPurelab Ultra system. 
 
 
Figure 2.7: Cyclic Voltammogram for the Ferrocene Standard at 100 mV/ s with the arrows 
showing scan direction). 
 
The X-ray data for the metal complexes were recorded on a Bruker Apex Duo and an 
Oxford Diffraction Xcalibur 2 CCD 4-circle diffractometer equipped with an Oxford 
Instruments Cryojet operating at 120(2) K and 100(2) K and an Incoatec microsource 
operating at 30 W power. Data was collected with MoKα (λ = 0.71073 Å) radiation at a 
crystal-to-detector distance of 50 mm. The data collection on the Oxford diffractometer 
was performed using omega scans at θ = 29.389° with exposures taken at 2.00 kW X-
ray power and 0.75° frame widths using CrysAlis CCD [5]. The data were reduced 
with CrysAlis RED Version 170 [5] using outlier rejection, scan speed scaling, as well 
as standard Lorentz and polarization correction factors. A semi-empirical multi-scan 
absorption correction [6] was applied to the data. The following conditions were used 
for the Bruker data collection: omega and phi scans with exposures taken at 30 W X-
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ray power and 0.50º frame widths using APEX2 [7]. The data were reduced with the 
programme SAINT [8]  using outlier rejection, scan speed scaling, as well as standard 
Lorentz and polarisation correction factors. A SADABS semi-empirical multi-scan 
absorption correction was applied to the data [6]. Direct methods, SHELXS-97 [9] and 
WinGX [10] were used to solve all structures. 
 
Computational calculations were conducted with Gaussian 09W software [11]. The 
geometry optimizations of the complexes were accomplished at the Density 
Functional Theory level using the B3LYP correlation functional, the LANL2DZ and 
the 6-311G++ (d, p)  basis sets [11-15]. 
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Chapter 3 
Ruthenium(II) and (IV) Complexes with potentially 




Pyrimidines are known to have a wide variety of biological activities and some are 
endowed with antitumour, antiviral and antifungal properties [1]. Of particular 
interest to us is 5,6-diamino-1,3-dimethyl uracil (H2ddd), see Figure 3.1, which is an 
analogue of the established chemotherapeutic drug, uracil mustard [2]. It has 
previously been shown that Schiff base derivatives of H2ddd have diverse 
coordination modes toward other transition metals, such as rhenium, in both high and 








Figure 3.1: Structure of 5,6-diamino-1,3-dimethyl uracil (H2ddd). 
 
Ruthenium compounds with derivatives of uracil and other nucleotide bases are 
known, e.g. the ruthenium(III) compounds, [RuCl4(DMSO)[H-LA)]] {LA = N6-
pentyladenine, N6-hexyladenine or N6,N6-dibutyladenine} [5, 6, 7]. The study of 
transition metals with nucleotide bases are important as it aids in the understanding 
of the mechanisms of these metals towards the metabolism of nucleic acids. The 
coordination of ruthenium with various nucleotides have revealed that the metal 
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interacts with the N(7) of the purines, the N(3) of the pyrimidines and could possibly 
metabolize DNA in a similar manner to that of platinum metal, which is used in the 
successful drug Cisplatin [8]. 
 
In this chapter, the coordination behaviour of various Schiff bases synthesized from a 
derivative of the biologically relevant moiety, uracil [viz. 5,6-diamino-1,3-dimethyl 
uracil (H2ddd)], towards ruthenium(II) were explored (see Figure 3.2). The ruthenium 
complexes trans-[RuIICl(PPh3)2(Htdp)] (1), trans-[RuIICl(PPh3)2(Hsdp)] (2) and 
[RuIICl(PPh3)(H3ucp)] (3) were isolated from reactions with the Schiff bases 5-
((thiophen-3-yl)methyleneamino)-6-amino-1,3-dimethyluracil (H2tdp), 5-(2-
(methylthio)benzylideneamino)-6-amino-1,3-dimethyluracil (H2sdp) and 2,6-bis-((6-
amino-1,3-dimethyluracilimino)methylene)pyridine (H4ucp), respectively. Schiff base 
hydrolysis occurs upon reacting 5-(2-hydroxybenzylideneamino)-6-amino-1,3-










































3.2.1 Synthesis of trans-[RuCl(PPh3)2(Htdp)] (1) 
H2tdp (0.0276 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.100 g; 0.104 mmol) were 
refluxed for 3 hours in methanol (20 cm3). While the brick-red solution was allowed 
to cool to room temperature, red crystals grew in the mother liquor, and were filtered 
and washed with anhydrous diethyl ether. These crystals were dissolved in 
dichloromethane and layered with hexane. The slow diffusion of hexane into the DCM 
solution afforded cubic-shaped crystals which were suitable for X-ray analysis. Yield 
= 52% based on Ru; m.p. 240.7–242.4°C. Molar conductivity (DCM, 10−3 M) = 3.003 
ohm-1 cm-2 mol-1. IR (νmax cm−1): ν(N–H) br, 3182, ν(C=O) 1711, ν(C=N) 1665, ν(C=C) 
1576, ν(thiophene) 1456, 1436 and 1368, v(Ru-[PPh3]2) 746 and 696. 1H NMR (295 K/d3-
CD3CN/ ppm): 12.72 (s, 1H, NH), 7.71–7.62 (m, 4H, H1, H2, H3, H5), 7.51–7.29 (m, 30H, 
2x PPh3), 3.03 (s, 3H, CH3), 2.78 (s, 3H, CH3). 31P NMR (295 K/d3-CD3CN ppm): 15.28. 
UV–Vis (DCM, λmax (ε, M−1 cm−1)): 284 nm (32864), 406 nm (2265), 507 nm (9385). 
 
3.2.2 Synthesis of trans-[RuCl(PPh3)2(Hsdp)] (2) 
Equimolar amounts of H2sdp (0.0318 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.100 g; 
0.104 mmol) were refluxed for 3 hours in methanol (20 cm3). The resultant cherry-red 
solution was allowed to cool to room temperature, and the red crystals were filtered 
by gravity. These crystals were recrystallized via slow diffusion in a chloroform and 
hexane (1:1) v:v solution. Yield = 61% based on Ru; m.p. 208.4–210.2 °C. Molar 
conductivity (DCM, 10−3 M) = 10.31 ohm-1 cm-2 mol-1. IR (νmax cm−1): ν(N–H) br, 3398, 
ν(S–CH3) 3066 ν(C=O) sh, 1705, ν(C=N) 1671, ν(C=C) 1577, v(Ru-[PPh3]2) 743 and 695. 
1H NMR (295 K/d3-CD3CN/ppm): 12.67 (s, 1H, NH), 8.01 (br, s, 1H, H1), 7.75–7.52 (m, 
4H, H2, H3, H4, H5), 7.51–7.16 (m, 30H, 2x PPh3), 6.90 (br, s, 3H, SCH3), 3.04 (s, 3H, 
CH3), 2.77 (s, 3H, CH3). 31P NMR (295 K/d3-CD3CN/ppm): 24.61. UV–Vis (DCM, (λmax 






3.2.3 Synthesis of [RuCl(PPh3)(H3ucp)] (3) 
A mixture of H4ucp (0.0458 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.100 g; 0.104 
mmol) in methanol (20 cm3) was heated under reflux for 3 hours. A maroon precipitate 
was filtered by gravity, dissolved in dichloromethane and the resultant solution was 
layered with hexane. After several days of slow diffusion red cubic crystals, which 
were ideal for X-ray analysis, were attained. Yield = 73% based on Ru; m.p. 271-274 
°C.  Molar conductivity (DMF, 10-3 M):  11.17 ohm-1 cm-2 mol-1. IR (νmax/cm-1): v(N-H) 
3320, 3161, ν(C=O) 1686 (s), ν(C=N) 1618 (s), ν(Ru-PPh3) 696 (m); 1H NMR (295K/ d6-
CD6SO/ ppm): 8.59 (s, 1H, H7), 8.31 (s, 1H, H13), 7.85 (br, s, 2H, N3H2), 7.46 – 7.21 (m, 
15H, PPh3), 7.17 (d, 1H, H9), 7.03 (d, 1H, H11), 6.83 (t, 1H, H10), 5.77 (s, 1H, N7H) 3.55 
(s, 3H, C3H3), 3.03 (s, 6H, C1H3, C16H3), 2.79 (s, 3H, C18H3); 31P NMR (295K/ d6-
CD6SO/ppm): 36.89. UV-Vis (DMF, λmax (ε, M-1cm-1)): 267 nm (sh, 20531); 387 nm 
(7136); 419 nm (sh, 6777); 474 (sh, 4769); 556 nm (sh, 3789). 
 
3.2.4 Synthesis of cis-Cl, trans-P-[RuCl2(PPh3)2(ddd)] (4) 
A 1:1 molar reaction of H3hdp (0.029 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] (0.100 g; 
0.104 mmol) were refluxed for 3 hours in methanol (20 cm3). The dark maroon solution 
was allowed to cool to room temperature; dark red crystals were filtered and washed 
with anhydrous diethyl ether. These crystals were dissolved in dichloromethane and 
layered with hexane and the resultant solution was allowed to stand for several days. 
From slow diffusion of hexane into the DCM solution, XRD quality red crystalline 
parallelograms were afforded. Yield = 62% based on Ru; m.p. 207.9–209.0 °C. 
Conductivity (DCM, 10−3 M) = 9.433 ohm-1 cm-2 mol-1. IR (νmax cm−1): v(N–H) 3052, 
3148, v(C=O) 1712, ν(C=C) 1579, v(Ru-[PPh3]2) 743 and 697. UV–Vis (DCM, (λmax (ε, 









3.3 X-Ray Crystallography 
 
The X-ray diffraction data for 1 was recorded on an Oxford Diffraction Xcalibur 2 CCD 
4-circle diffractometer equipped with an Oxford Instruments Cryojet operating at 
120(2) K. The X-ray data for 3 and 4 were collected on a Bruker Apex Duo equipped 
with an Oxford Instruments Cryojet and an Incoatec microsource operating at 30 W 
power which were operated at 100(2) K. The data was reduced with CrysAlis RED 
Version 170 [9] and SAINT [10] and the structures were solved using SHELXS-97 [11] 
as well as WinGX [12]. All non-hydrogen atoms were located in the difference density 
map and refined anisotropically with SHELXL-97 [11]. All hydrogens of the 
ruthenium complexes 1 and 3 were included as idealized contributors in the least-
squares process. Their positions were calculated using a standard riding model with 
C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq and the solvent C-H bonds were located 
in the difference density map and refined isotropically.  For 4, OLEX 2 was utilized 
where the hydrogens were treated by a mixture of independent and constrained 
refinement [13]. The crystal structure refinement data are given in Table 3.2 while the 
selected bond lengths and angles are shown in Tables 3.3 and 3.4. 
 
3.4 Computational Details 
 
Computational calculations were conducted using the Gaussian 09W software [14]. 
Geometry optimization of the ruthenium complex 3 was achieved through DFT 
calculations using the B3LYP functional, with an accompanying hybrid basis set viz. 
the 6-311G++ (d, p) basis set was applied to all the C, H, N, O, Cl and P atoms and the 
LANL2DZ basis set applied to the metal centres [15]. Prior to the calculation, the 
solvent molecule of recrystallization was removed from the crystal structure and the 
resultant structure was used as the starting conformer. Good agreement was found 
between the optimized and geometrical parameters (refer to Table 3.4) with the minor 
deviations due to the fact that gas phase optimized structures does not account for 
non-classical hydrogen bonding interactions or any short distance contacts. Using the 
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optimized structure of the metal complexes, frequency calculations confirmed that the 
structure is at global minima on the potential energy surfaces [16].  
 
3.5 Results and Discussion 
 
3.5.1 Synthesis and Spectral Characterization 
 
Equimolar reactions between trans-[RuIICl2(PPh3)2] with H2tdp, H2sdp, H4ucp and 
H3hdp led to variable valence ruthenium(II/IV) complexes, trans-
[RuIICl(PPh3)2(Htdp)] (1), trans-[RuIICl(PPh3)2(Hsdp)] (2), [RuCl(PPh3)(H3ucp)] (3) 
and trans-P, cis-Cl-[RuIVCl2(PPh3)2(ddd)] (4), in moderate yields, respectively. In 1 and 
2, the Schiff base chelators (i.e. Htdp for 1 and Hsdp for 2) coordinate as monoanionic 
tridentate chelators whereas in 3, the H3ucp ligand coordinates as a monoanionic 
tetradentate chelator. In the case of 4 the initial Schiff base (H3hdp) hydrolyzed to 
afford the ddd chelator which is a bidentate dianionic moiety. In the preparation of 4, 
no precaution was taken to ensure that the reaction was performed with a dry solvent 
and in an inert atmosphere which led to the hydrolysis of H3dhp to form ddd. The 
resulting ddd ligand induced oxidation of the metal centre upon coordination. 
 
For 1 and 2, the equatorial plane is occupied by the NNS donors of the Htdp and Hsdp 
ligands respectively; leaving one remaining position for the chloride (see Figure 3.3). 
For 4, the ddd moiety affords a five-membered chelate ring through its NN-donor set 
trans to the cis chlorides (see Figure 3.3). The bulky PPh3 ligands are trans-axial thereby 
minimizing steric repulsion. This orientation is typical for ruthenium Schiff base 
complexes containing the trans-[Ru(PPh3)2] core, e.g. trans-[Ru(Rcb)CO(Cl)(PPh3)2] 
{HRcb = N-[(dialkyl/aryl)carbamothioyl]benzamide} [17]. In an attempt to isolate 
octahedral saturated ruthenium complexes (i.e. “3 + 3” coordination modes), by 
utilizing higher molar ratios of the respective ligands with respect to the metal 
precursor, the same metal complexes (i.e. 1, 2 and 4) were isolated. Recently, the “3 + 
3” ruthenium(III) compounds, [Ru(Ln)2]ClO4{(HLn = 4-R-2-((2-(pyridin-2-
yl)hydrazono)methyl)phenol, R = H, Cl, Br, Me, and OMe}, have been reported [18, 
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19]. In contrast, for 3, the tetradentate H3ucp ligand displaces all the equatorial co-
ligands of the metal precursor by coordinating through the bridging nitrogen pyridyl 
































Figure 3.3: Coordination modes of the Schiff base chelates. 
 
 
The Schiff bases were only soluble in DMF and DMSO, but complexes 1, 2 and 4 
exhibit good solubility in most polar solvents and are non-electrolytes in DCM. 
Complex 3 dissolves readily in chlorinated solvents but exhibit partial solubility in 
other polar solvents such as methanol, ethanol and acetonitrile and displays a high 
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molar conductivity value typical of a 1:1 complex salt [20]. NMR spectroscopy for the 
ligands (in d6-DMSO) and complexes (d3-CD3CN) was done in different deuterated 
solvents, since no interpretable NMR spectra could be obtained in deuterated DMSO 
for 1 and 2. Diamagnetism for 1, 2 and 3 can be clearly seen from their respective well-
resolved signals, whereas the paramagnetic 4 showed broadened signals with low 
intensity.  
 
The 1H NMR spectra for the diamagnetic complexes were dominated by multiplets 
(7.51–7.29 ppm for 1, 7.51–7.16 ppm for 2 and 7.46–7.21 ppm for 3) due to the 
triphenylphosphine co-ligands which are upfield relative to the multiplets of the 
aromatic signals for the Schiff base chelators (see Figures 3.4 and 3.5).  Confirmation 
of coordination is clearly observed by the disappearance of the broad uracil-amino 
group singlets (6.96 ppm for H2tdp, 3.19 ppm for H2sdp and 7.46 ppm for H4ucp) and 
the appearance of sharp singlets (12.72 ppm for 1 and 12.67 ppm for 2) downfield due 
to the deprotonated form of the uracil-amino group as well as the emergence of two 
singlets (in 3) which is assigned to the amino (at 7.85 ppm) and amido (at 5.77 ppm) 
protons. Further evidence arises from the imino singlets which are at lower 
frequencies (for 1 the signal is part of a 7.71–7.62 multiplet and for 2 at 8.01 ppm), in 
comparison to the free Schiff bases (for H2tdp at 9.79 ppm and for H2sdp at 10.08 ppm). 
The splitting of the imino protons signal for the H3ucp chelator is a reflection of the 
asymmetry within the coordination sphere of 3. Similarly, the up-field shifts of the 
aromatic signals of 3 relative to those of the free-ligand affirm coordination of the 
H3ucp tetradentate chelator. 31P NMR spectroscopy confirmed the presence of the 
phosphorous atoms in 3 and magnetic equivalence was observed for the trans-axial 
triphenylphosphine co-ligands from the 31P NMR spectra of 1 and 2 since only a single 





Figure 3.4: 1H NMR spectrum of complex 2, in the range of 13.0 – 6.0 ppm. 
 
 




IR spectra of all the complexes show the intense peaks of the trans-[Ru(PPh3)2] unit 
found nearly at the same positions between 750 and 695 cm−1 [21]. Consistent with the 
1H NMR spectral analysis, coordination is also affirmed based upon shifts observed 
in IR spectra of 1 and 2 (see Figures 3.6 and 3.7) relative to their free Schiff bases. The 
imino stretching bands shift to higher frequencies (e.g. from 1611 cm−1 in H2tdp to 1665 
cm−1 in 1) upon coordination. In addition, shifts were also observed for the intense 
bands of the tdp chelator in 1, the ν(S-CH3) in 2 and the υ(C=O) in 3 (see Figure 3.8) 
relative to their respective free ligands. For 4 (see Figure 3.9) the disappearance of the 
Schiff base moiety (for H3hdp at 1608 cm−1) supports the fact that hydrolysis occurred. 
Furthermore, only one broad ν(N-H) stretching band was found for the diamagnetic 




















Figure 3.9: Overlay IR spectra of the free-ligand, H2hdp and complex 4 between 1750 and 
650 cm-1. 
 
The highly delocalized Schiff base chelators afford similarities between the UV/Vis 
spectra of the free Schiff bases and their metal complexes (see Figures 3.10-3.13). A 
series of common intra-ligand electronic transitions were observed for complexes 1, 2 
and 4 between 280 and 410 nm while the spectrum of 3 is dominated by only ligand-
based electronic transitions. Broad Metal-to-Ligand Charge Transfer (MLCT) bands 
are found for complexes 1, 2 and 4 at 507, 509 (for the d6 metal complexes 1 and 2 
respectively), and 515 nm for the d4 metal complex 4. These MLCT bands are typical 
of octahedral Ru(II/IV) complexes with aromatic chelating moieties [22, 23]. No d-d 
transitions are found for the diamagnetic complexes, which is due to their low-spin d6 
electron configurations. The same trend was observed with the paramagnetic d4 






Figure 3.10: Overlay UV/Vis spectra of complex 1 and its ligand, H2tdp. 
 
 





Figure 3.12: Overlay UV/Vis spectra of complex 3 and its ligand, H4ucp. 
 
 




As expected, ruthenium(II) complexes (1, 2 and 3) exhibit ESR silent diamagnetic 
behaviour due to their non-variable spin states (S = 0), but ruthenium(IV) complexes 
can exhibit both diamagnetic (S = 0) and paramagnetic (S = 1) spin states depending 
on the nature of the ligand. A broad singlet (giso-value = 2.0757) observed in the X-
band spectrum of 4 (see Figure 3.14) unequivocally confirms the presence of the 
paramagnetic Ru(IV) center. Similar to 4, the one-electron electrochemically oxidized 
species (at 295 K) of [RuIIIQ3] {Q = 3,5-di-tert-butyl-o-quinone} and [RuIII(Qx)] {Qx = 
4,6-ditert-butyl-N-phenyl-o-iminobenzoquinone} afforded isotropic singlets with giso 
= 1.991 and 2.001, respectively [24]. 
 
 
Figure 3.14: X-band EPR spectrum of 4 at 298 K. Instrument settings: microwave bridge 
frequency, 9.8 GHz; microwave bridge attenuator, 20 dB; modulation frequency, 100 kHz; 




Each complex showed a single redox couple which exhibited diffusion controlled 
behaviour at increasing scan rates. For example, see Figures 3.15 and 3.16 for the 
overlay cyclic voltammograms of 3 and 4 with scan rates ranging from 100 to 300 
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mV/s, at increments of 25 mV. Peak current ratios approaching one were observed for 
all complexes, implying that the redox couples are for one-electron redox processes. 
More interestingly, it is observed that 1 and 3 have smaller peak to peak separations 
(ΔE = 80 mV for 1 and ΔE = 50 mV for 3, refer to Table 3.1) than ferrocene (ΔE = 90 
mV), which indicates faster electron transfer kinetics. However, slow electron transfer 
kinetics were observed for 2 and 4 which indicate quasi-irreversibility with peak to 
peak separations of 110 and 100 mV, respectively (see Figure 3.17). 
 
Table 3.1: Selected CV Parameters (at 100 mV/s) for 1, 2, 3 and 4. 
 E½/V ΔE/mV 
Ferrocene 0.495 90 
1 0.70 80 
2 0.725 110 
3 0.37 50 
4 0.68 100 
 
 





Figure 3.16: Overlay CVs of complex 4 at incrementing scan rates. 
 
 
Figure 3.17: Overlay Cyclic Voltammograms of 1, 2, 3 and 4 as well as for the ferrocene 





The redox couples of the complexes are ascribed to metal-based processes as they had 
similar half-wave potentials to other ruthenium complexes with Schiff base chelates. 
These literature trends show that for 1, 2 and 3 the redox couple Ru(II/III) is observed, 
whereas for 4 it had similar half-wave potentials to ruthenium(III) compounds 
ascribed to the Ru(III/IV) redox couple. For example, in the case for the complexes, 
trans-[RuII(RL)(PPh3)2(CO)Cl] {HRL = (2-benzylimino-methyl)-4-R-phenol, R = H, Cl, 
Br or OMe}, which displays quasi-reversible metal centred processes in DCM between 
0.62 and 1.16 V (E½ versus Ag|AgCl). The variable half-wave potentials are accounted 
to diverse electronic properties of R. When R had electron withdrawing character, a 
higher oxidation potential was induced and a reverse trend was found for electron 
donating R [25]. Paramagnetic ruthenium(III) compounds trans-[RuIII(L)(PPh3)2Cl] in 
DCM showed comparable Ru(III/IV) redox couples (versus Ag|AgCl) [26]. 
 
3.5.3 Crystal Structures 
 
(a) Crystal Structure of 1 
 
The metal is at the centre of a distorted octahedron with the basal plane defined by 
four donors, ClSN1N2, while the axial plane constitutes the trans triphenylphosphines 
(see Figure 3.18). The distortion is enforced by the Htdp tridentate chelator (within 
the basal plane), which affords two constrained five-membered chelate rings [S-Ru-
N2 = 80.9(7)° and N1-Ru-N2 = 78.8(1)°]. As a result, the equatorial bond angles [Cl-
Ru-N2 = 167.66(7)° and S-Ru-N1 = 159.14(8)°] deviate considerably from linearity. 
Inevitably, the N1-Ru-N2 bite angle induces a wider C6-N2-C6 [123.5(3)°] bond angle 
than the ideal 120° for a bridging sp2 hybridized nitrogen. However, the C(5)=N(2) 
bond distance of 1.313(4) Å is indicative of a Schiff base coordinated to ruthenium(II) 
[18, 24]. The metal amido [Ru-N1 = 2.036(3) Å] bond is shorter than the metal imino 
[Ru-N2 = 2.053(2) Å] bond as expected, with the latter comparable to ruthenium(II) 
complexes with Schiff base chelates [18, 24]. For example, a Ru–Nimino bond of 2.084(3) 
Å was observed for [RuII(L3)(CO)(PPh3)] [27]. The nearly equidistance Ru–P bonds of 




Thiophene ligands exhibit diverse coordination modes ranging from ŋ1(S), ŋ1(C), 
ŋ2(C2), ŋ4(C4), and ŋ5(C4S). A bond distance of 2.362(1) Å for the Ru-S bond is typical 
of ŋ1(S) coordination. The Ru–Sthienyl bond was similar to [Ru(bpy)2-Y-P,S](PF6)2, where 
for Y = PT3 (3-(diphenylphosphino)-2,2-terthiophene) or Y = PMe2T3 (5,5-dimethyl-3-
(diphenylphosphino)-2,2:52-terthiophene) the bond distances were 2.346(1) and 
2.362(2) Å, respectively [28]. The sp3 hybridized sulfur induces longer C–S [C1-S = 
1.725(3) and C4-S = 1.749(3) Å] bond lengths within the thiophene ring, in comparison 
to delocalized C-S bonds found for uncoordinated thiophene rings. This implies that 
delocalization only occurs through the thiophene ring carbons, which is evident from 
the respective bond distances [C1-C2 = 1.353(4), C2-C3 = 1.426(4) and C3-C4 = 1.362(5) 
Å]. This was also observed for [RuII(bpy)2(dppe-terth-P,S)](PF6)2 {bpy = 2,2-bipyridyl, 
dppe-terth = 3-(diphenylphosphino)-2,2:5’2-terthiophene] which had longer 
interthiophene ring C-S [1.744(3) and 1.751(3) Å] bond distances than its analogous 
compound, [RuII(bpy)2(dppeterth- P,C)](PF6)2,with C-S bond distances of 1.720(6) and 
1.735(1) Å [29]. The thiophene moiety of 1 lies out of the basal plane by 31.14°, which 
could be induced either by the break in delocalization between the bridging C-S-C 
within the ring system or the pi-stacking [interplanar spacing = 3.696 Å] between the 
thiophene ring and the C12-C17 phenyl ring of the triphenylphosphine co-ligand. 




Figure 3.18: An ORTEP view of 1 showing 50% probability displacement ellipsoids and the 
atom labeling. Hydrogens were omitted for clarity. 
 
 
(b) Crystal Structure of 3·CH2Cl2 
 
The octahedron of 3 is defined by the N4-donor set of the monoanionic H3ucp chelator 
occupying the equatorial plane while the axial plane is defined by the ClRuP atoms. 
The octahedron of 3 is severely distorted as a result of the combined effect of the three 
five-membered chelate rings which results in the formation of three constrained bite 
angles [N4-Ru-N5 = 76.4(1)⁰, N5-Ru-N6 = 81.2(1)⁰ and N6-Ru-N7 = 79.1(1)⁰] which 
induces non-linear N4-Ru-N6 [157.4(1)⁰] and N5-Ru-N7 [159.9(1)⁰] bond angles (see 





Figure 3.19: An ORTEP view of complex 3 showing 50 % probability displacement 
ellipsoids and the atom labelling. The hydrogen atoms were omitted for clarity. 
 
The axial Cl-Ru-P [172.96(3)⁰] bond angle is influenced by classical π-π stacking 
between the uracil rings and selected phenyl groups of the PPh3 co-ligand given by 
the interplanar spacings of 3.431 Å (I) and 3.430 Å (II), see Figure 3.20. Furthermore, 
the intramolecular interactions cause the uracil moiety to lie substantially out of the 
N4-equotorial plane (at 42.64⁰). The bridging pyridyl nitrogen to ruthenium [1.957(5) 
Å] and Ru-Cl [2.4507(15) Å] bonds of trans-[Ru(Cl)(btrpy)(PPh3)2]PF6 (btrpy = 4,4’,4’-
tri-t-butyl-2,2’:6’,2’’-terpyridine) are similar to the Ru-N5 [1.954(4) Å] and the Ru-Cl 
[2.476(3) Å]  bond distances of 3 [30]. The metal-amido bond distance of 3 [Ru-N7 = 
2.143(4) Å] is within the range of 2.036(3)-2.292(9) Å found for other amido 
ruthenium(II) complexes [31, 32]. Interestingly, a large difference in the metal-imino 
bond distances [Ru-N4 = 2.189(3) Å and Ru-N6 = 2.001(3) Å] is noted and this 
phenomena extends also into the bond distances of the Schiff base moieties [N4-C7 = 





Figure 3.20: Demonstration of the intramolecular interactions occurring in complex 3; given 
as I = 3.431 Å and II = 3.430 Å. 
 
To understand these geometrical discrepancies, the geometry of 3 was optimized at 
the DFT level. The difference in the theoretical bond distances of Schiff base moieties 
[N4-C7 = 1.3010 Å and N6-C13 = 1.3225 Å] is also reflected in the optimized structure 
of 3. The longer bond distance of the N6-C13 appears to emanate from the C13-N6-
C14 delocalized π-system as opposed to localized N4-C7 double bond. This 
observation is further supported by shorter bond length of N6-C14 [1.3676 Å for 
optimized structure and 1.388(5) Å for crystal structure] compared to N4-C5 [1.4115 
Å for optimized structure and 1.420(5) Å for crystal structure] observed within both 
the crystal and optimized structures which implies the latter exhibits single bond 
character. Consequently, the variable Natural Population Analysis (NPA) of the imino 
nitrogens [N4 = -0.392 and N6 = -0.282] are computed which results in the differences 
in the optimized [Ru-N4 = 2.3055 Å and Ru-N6 = 2.0196 Å] and experimental [Ru-N4 
= 2.189(3) Å and Ru-N6 = 2.001(3) Å] Ru-Nimino bond distances.  Several ruthenium 
compounds with derivatives of uracil and other nucleotide bases have been isolated, 
e.g. the arene ruthenium cationic compound, [RuII(Ur=C=C)(PPh3)2(η5-C5H5)](PF6) 
which was formed from the uracil (Ur)-substituted alkyne Ur-C≡CH, NH4PF6 and 
[Ru(PPh3)2(η5-C5H5)Cl] [5]. Another example is the paramagnetic ruthenium(III) 
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compound, trans-[RuCl4(DMSO)(H2mtpo)].4H2O which was isolated from the 
reaction between the adenine derivative,  5-methyl-1,2,4-triazolo[1,5-α]pyrimidin-
7(4H)-one (H2mtpo) and [H(DMSO)2][trans-Ru(DMSO)2Cl4] [33]. 
 
(c) Crystal Structure of 4·CH3Cl 
 
Complex 4 co-crystallizes with a chloroform molecule in a triclinic unit cell (see Figure 
3.21). Within the N1N2Cl1Cl2 basal plane, the small N1-Ru-N2 [78.0(1)°] bite angle 
causes the chlorides to be further apart resulting in a Cl1-Ru-Cl2 angle [97.64(2)°] 
deviating from the ideal 90° angle. This is not surprising as the geometrical parameters 
of the five-membered chelate ring of 4 were similar to those found in the chelate rings 
of the ruthenium(II) bipyridine (bpy) complex, cis-[Ru(bpy)2(CO)(OH2)] [34]. The 
constrained five-membered chelate ring resulted in a non-ideal octahedron where the 
basal plane trans angles [Cl1-Ru-N1 = 175.29(8)° and Cl2-Ru-N2 = 164.70(7)°] angles 
deviate from linearity. Although no difference in steric hindrance between 1 and 4 that 
influences trans-axial linearity is observed, a smaller angle was observed for 4 [P1-Ru-
P2 = 170.34(2)°] relative to 1 [175.28(3)°]. This larger difference in linearity for 4 could 
be ascribed to a weak intermolecular interaction between almost co-planar ring 
systems (centroid to centroid distance = 3.950 Å) of ddd and the C7–C12 phenyl ring 
of the P2-triphenylphosphine. This might also account for the small differences in 
bond distances found for the Ru-P bonds [Ru-P1 = 2.3878(7) and Ru-P2 = 2.4006(7) Å] 





Figure 3.21: An ORTEP view of 4 showing 50% probability displacement ellipsoids and the 
atom labelling. The solvent of recrystallization has been omitted for clarity. 
 
Noteworthy, the coordination sphere bond distances within the basal plane for 4 are 
shorter than in 1 due to stronger Lewis acid character of ruthenium(IV). The metal 
amido bonds [Ru-N1 = 2.017(3) and Ru-N2 = 1.969(3) Å] are not equal, due to the 
better electron withdrawing group next to N2, which causes a shorter metal amido 
bond. The trans-influence of the amido nitrogens on chlorides is different, with 
dissimilar metal to chloride bonds [Ru-Cl1 = 2.4218(7) and Ru-Cl2 = 2.4361(8) Å]. 
Several examples are found in literature of ruthenium(IV) compounds stabilized by 
amido donor chelates [35, 36]. Among these examples are [RuIV(bpy)(L–H)2](PF6)2 and 
[RuIV(L-H2)(L-H)2](ZnCl) {L-H2 = 2,3-diamino-2,3-dimethylbutane}, where a L-H 
moiety is a monoanionic bidentate chelator. These compounds were isolated from 
chemical oxidations via liquid bromine using the metal precursor, [RuII(bpy)(L–
H2)2](X); X = PF6 or ZnBr4 [37]. 
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Table 3.2: Crystal Data and Structure Refinement Data for Complexes 1, 3 and 4. 
 1 3·CH2Cl2 4·CHCl3 
Chemical formula C47H41ClN4P2RuS C38H37Cl3N9O4PRu C42H38Cl2N4O2P2Ru.CHCl3 
Formula weight 924.36 922.16 984.1 
Temperature(K) 120(2) 100(2) 100(2) 
Crystal system P21/n P-1 P-1 
Space group Monoclinic Triclinic Triclinic 
Unit cell dimensions (Å, °) a = 15.0390(50) a = 12.3357(5) a = 12.5444(6) 
 b = 17.3710(50) b = 12.7812(7) b = 12.9786(7) 
 c = 16.0210(50) c = 15.8388(6) c = 14.9529(8) 
 α = 90.000(5) α = 68.056(2) α = 71.528(3) 
 β = 105.876(5) β = 75.651(2) β = 72.450(3) 
 γ = 90.000(5) γ = 79.853(2) γ = 71.853(2) 
Crystal size (mm) 0.20×0.10×0.10 0.20x0.12x0.08 0.4×0.05×0.05 
V(Å3) 4026(2) 2234.32 2137.89(19) 
Z 4 2 2 
Density (calc.) (Mg/m3) 1.525 1.368 1.53 
Absorption coefficient (mm-1) 0.634 0.613 0.796 
F(000) 1896 936 1000 
θ range for data collection (deg) 2.87–26.06 1.41-26.06 1.5–27.0 
Index ranges −18 ≤ h ≤ 17 
−21 ≤ k < 20 
−19 ≤ l ≤ 19 
-15 ≤ h ≤ 15 
-15 ≤ k < 10 
-19 ≤ ℓ ≤ 19 
−15 ≤ h ≤ 15 
−16 ≤ k < 16 
−16 ≤ l ≤ 18 
Reflections measured 29767 21876 25651 
Observed reflections [I>2σ(I)] 5483 8487 6780 
Independent reflections 7957 7451 7696 
Data/Restraints/parameters 7957/0/529 7451/0/521 7696/2/524 
Goodness of fit on F2 0.862 1.059 1.003 
Observed R, wR2 0.0360, 0.0756 0.0478, 0.1369 0.033, 0.083 






Table 3.3: Selected bond lengths [Å] and angles [°] for 1 and 4. 
1  4·CHCl3  
Ru–N1 2.036(3) Ru–N1 2.017(3) 
Ru–N2 2.053(2) Ru–N2 1.969(3) 
Ru–Cl 2.4517(9) Ru–Cl1 2.4218(7) 
Ru–P1 2.395(1) Ru–Cl2 2.4361(8) 
Ru–P2 2.372(1) Ru–P1 2.3878(7) 
Ru–S 2.362(1) Ru–P2 2.4006(7) 
C5–N2 1.313(4) N1–Ru–N2 78.0(1) 
C1–S 1.725(3) Cl1–Ru–Cl2 97.64(2) 
C4–S 1.749(3) Cl1–Ru–N1 175.29(8) 
C1–C2 1.353(4) Cl2–Ru–N2 164.70(7) 
C2–C3 1.426(4) P1–Ru–P2 170.34(2) 
C3–C4 1.362(5) - - 
S–Ru–N2 80.9(7) - - 
N1–Ru–N2 78.8(1) - - 
Cl–Ru–N2 167.66(7) - - 
S–Ru–N1 159.14(8) - - 
C6–N2–C6 123.5(3) - - 














Table 3.4: Selected bond lengths [Å] and bond angles [°] for 3. 
 Experimental  Optimized 
Ru-N5 1.954(4) 1.9863 
Ru-Cl 2.476(3) 2.5027 
Ru-N7 2.143(4) 2.1799 
Ru-N4 2.189(3) 2.3055 
Ru-N6 2.001(3) 2.0196 
N4-C7 1.314(5) 1.3010 
N6-C13 1.324(5) 1.3225 
N4-C5 1.420(5) 1.4115 
N6-C14 1.388(5) 1.3676 
Ru-P 2.294(1) 2.3683 
N4-Ru-N5 76.4(1) 75.30 
N5-Ru-N6 81.2(1) 80.88 
N6-Ru-N7 79.1(1) 78.54 
N4-Ru-N6 157.4(1) 155.50 
N5-Ru-N7 159.9(1) 159.05 
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Chapter 4          S Maikoo 
Chapter 4 
Novel Ruthenium(II) and (III) Compounds with 
Multidentate Schiff Base Chelates bearing the 
Chromone or 4-Aminoantipyrine Moieties 
4.1 Introduction 
 
There is no doubt that the chromone or antipyrine moieties have been receiving 
increasing attention for the design of novel organic and inorganic-based 
pharmaceuticals [1 - 5], see Figure 4.1. Their abundant biological activities originates 
from the structural similarities of the pyrazolone derivative and antipyrine with 
natural imidazole containing constituents which often results in inherent biological 
activities while chromone is a secondary metabolite. In addition, numerous examples 
in literature have shown that the inclusion of these biologically significant moieties 
promoted DNA intercalation. For example, DNA binding activities were observed for 
both the metal complexes, [NiO3(L)] (L = 6-hydroxychromone-3-carbaldehyde 
thiosemicarbazone) and [CuL1] (L1 = hydroxy-benzylidene-4-aminoantipyrine) and 









Figure 4.1: Molecular structures of chromone and antipyrine. 
 
Many ruthenium complexes, containing Schiff bases derived from 4-aminoantipyrine 
and chromone, display a vast biological properties. Examples of these are the 
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organometallic ruthenium complexes, [RuCl2(DMSO)2(4-aminoantipyrine)], which 
contains the O, N chelate of the 4-aminoantipyrine ligand, which has shown optimal 
DNA binding activity towards herrings sperm DNA [8, 9] and [Ru(phen)2(MCMIP)]2+ 
(phen = 1, 10-phenanthroline;  MCMIP = 2-(6-methyl-3-chromonyl)imidazo[4,5-
f](1,10-phenanthroline) which was reported to bind to DNA and cause cleavage [10, 
11]. Another common observation for transition metal complexes containing these 
moieties is the coordination via the NSchiff baseOKeto donor atoms [3, 6].    
  
In this chapter, we report the formation of ruthenium(II) and( III) compounds with 
multidentate Schiff bases containing the 4-aminoantipyrine and chromone moieties. 
The ruthenium compounds, trans-P, cis-Cl-[RuIII(pch)Cl2(PPh3)2] (1) and cis-
[RuCl2(bpap)(PPh3)] (2)  were isolated from the coordination reactions of trans-
[RuCl2(PPh3)3] with the Schiff bases: 4-((pyridine-2ylimino)methylene)-chromone 
(pch) and 2,6-bis-((antipyrine-imino)methylene)pyridine (bpap) ligands, respectively. 
 
 




4.2.1 Synthesis of trans-P, cis-Cl-[Ru(pch)Cl2(PPh3)2] (1) 
A 1:1 molar reaction between pch (0.0261 g; 0.104 mmol) and trans-[RuCl2(PPh3)3] 
(0.100 g, 0.104 mmol) was heated at reflux in ethanol (30 cm3) for 3 hours. A blue 


















precipitate was dissolved in chloroform and layered with hexane and after several 
days, XRD quality blue parallelograms were attained using the slow diffusion 
method. Yield = 74% based on Ru, m.p. = 248 - 251°C.  IR (νmax/cm-1): ν(C=O) 1639 
(m), ν(C=N) 1613 (m), ν(C-O-C) 1508 (s), ν[Ru-(PPh3)2] 693 (s). UV-Vis (DMF, λmax (ε, 
M-1cm-1)): 271 nm (9925); 322 nm (4897); 386 nm (3758); 478 nm (sh, 792); 636 (349). 
Conductivity (DCM, 10-3 M): 78.74 ohm-1 cm-2 mol-1. 
 
4.2.2 Synthesis of cis-[RuCl2(bpap)(PPh3)] (2) 
The title compound was formed from the 1:1 molar ratio reaction of bpap (0.0527 g; 
0.104 mmol) and trans-[RuCl2(PPh3)3] (0.100 g, 0.104 mmol) in (20 cm3) toluene after 6 
hours of reflux. A dark brown precipitate was filtered and recrystallized via the slow 
diffusion of a dichloromethane and n-hexane [1:1 (v:v)] solution which resulted in the 
formation of brown XRD quality parallelograms. Yield = 63% based on Ru, m.p. = 323 
– 327°C.  IR (νmax/cm-1): ν(C=O) 1667, 1655, 1638 (s), ν(C=N) 1591 (s), ν(Ru-PPh3) 695 
(vs); 1H NMR (295K/ d6-CD6SO/ ppm): 8.21 – 8.02 (m, 5H, H12, H14, H15, H16, H18), 
7.60 – 6.62 (m, 25H, PPh3, H2, H3, H4, H5, H6, H25, H26, H27, H28, H29), 3.21 (s, 6H, 
C7H3, C9H3), 2.92 (s, 6H, C21H3, C22H3); 31P NMR (295K/ d6-CD6SO/ ppm): 31.22. UV-
Vis (DMF, λmax (ε, M-1cm-1)): 244 nm (sh, 26422); 279 nm (16393); 418 nm (4997); 498 
nm (sh, 2754); 599 nm (sh, 1352). Conductivity (DMF, 10-3 M):  15.39 ohm-1 cm-2 mol-1. 
 
4.3 X-Ray Crystallography 
 
The X-ray data for the metal complexes were recorded on a Bruker Apex Duo 
equipped with an Oxford Instruments Cryojet operating at 100(2) K and an Incoatec 
microsource operating at 30 W power. The data was reduced with the programme 
SAINT [12] and solved by direct methods using the SHELXS-97 [13] and WINGX [14] 
programmes. All non-hydrogen atoms were located in the difference density map and 
refined anisotropically with SHELXL-97 [13]. All hydrogen atoms were included as 
idealised contributors in the least squares process. Their positions were calculated 
using a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq.  
The amido N-H bond of 1 as well as the solvents’ C-H bonds of both complexes were 
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located in the difference density map and refined isotropically. Crystal and structure 
refinement data for the metal complexes 1 and 2 are given in Table 4.1. Selected bond 
lengths and angles are given in Tables 4.2 and 4.3. 
 
4.4 Results and Discussion 
 
4.4.1 Synthesis and Spectral Characterization 
The novel ruthenium compounds 1 and 2 were isolated from the equimolar 
coordination reactions of trans-[RuCl2(PPh3)3] with pch and bpap, respectively. The 
bpap ligand acts as neutral tridentate chelator which coordinates through its 
(Nimino)2Npy (in 2) donor set (see Figure 4.3 (2)). Interestingly for 1, the monoanionic 
pch chelator affords a constrained five-membered chelate ring through its formation 
of the ruthenium-carbene and the ruthenium-imino coordination bonds (see Figure 
4.3 (1)). Thus, in contrast to compound 2, which illustrates typical coordination affinity 
for pyridyl atoms, no pyridyl coordination bonding occurred for 1.   
 
 
Figure 4.3: Coordination modes of the pch (1) and bpap (2) ligands. 
 
The metal complexes dissolves readily in chlorinated solvents but exhibit partial 
solubility in other polar solvents such as methanol, ethanol and acetonitrile. Both 
complexes are non-electrolytes in dichloromethane. These conductivity 
















literature (13.5 – 18.4 ohm-1cm2mol-1 for Ru(II) and 42 - 202 ohm-1cm2mol-1 for Ru(III)] 
[15, 16]. The 1H NMR spectrum of 2 show two multiplets accounting for the bridging 
imino and pyridyl protons (between 8.21 and 8.02 ppm) and the phenyl protons 
(between 7.60 and 6.62 ppm) of the aminoantipyrine moieties (see Figures 4.4 and 4.5). 
The presence of the phosphorous atom in 2 were confirmed by a single peak observed 
at 31.22 ppm in the 31P NMR spectrum. This value is close to those found in literature 









Figure 4.5: 1H NMR spectrum of complex 2, in the range 6.31 - 8.66 ppm. 
 
No significant differences are observed between the IR spectra of the bpap ligand and 
its corresponding metal complex 2 as it contains neutral chelators (see Figure 4.7). In 
contrast for 1, the ketonic and ether bonds [ν(C=O) 1639 cm-1 and ν(C-O-C) 1508 cm-1] 
vibrates at higher frequencies compared to those of the free-ligand, pch [ν(C=O) 1647 
cm-1 and ν(C-O-C) 1557 cm-1] due to the difference in the steroelectronic properties 
between the monoanionic coordinated (in 1) and neutral uncoordinated chromone 
moieties (in the free ligand, pch), see Figure 4.6. In addition, the three strong imino 
bond vibrations (1611, 1603 and 1590 cm-1) of the free pch ligand coalesce into one 
medium-intensity vibration (at 1613 cm-1 for 2) upon coordination. The characteristic 







Figure 4.6: Overlay IR spectra of the free-ligand, pch and complex 1 between 1750 and 650 
cm-1. 
 





The highly delocalized nature of the Schiff base chelators of the complexes are 
emphasized by the several common intraligand π-π* electronic transitions observed 
within the overlay UV/Vis spectra of the free-ligands and their respective metal 
complexes, see Figures 4.8 and 4.9. These electronic transitions are found below 400 
nm. At more red-shifted wavelengths, metal-to-ligand charge transfer transitions 
were observed at 478 nm for 1 and 418, 498 and 599 nm for 2. As expected, a d-d 
electronic transition was observed for the paramagnetic ruthenium(III) complex 1 at 
636 nm in comparison to none observed for the low-spin d6 ruthenium(II) compound 
2. 
 
Figure 4.8: Overlay UV/Vis spectra of complex 1 and its ligand, pch. 
 
The presence of the paramagnetic ruthenium(III) centre in complex 1 was confirmed 
via room temperature solution (in DCM) ESR spectroscopy, see Figure 4.10. The 
deviation (between 3300 and 4000 G) from the typical rhombic ESR spectrum reflects 
distortion of the octahedral geometry of 1 [19, 20]. In fact, the g-value (2.0951) for 1 is 
similar to that attained in the poorly resolved solution ESR spectrum of the 
ruthenium(III) complex, trans-[RuCl(bzp)(PPh3)2] (Hbzp = N-(2-






Figure 4.9: Overlay UV/Vis spectra of complex 2 and its ligand, bpap. 
 
 
Figure 4.10: X-band EPR spectrum of 1 at 298 K. Instrument settings: microwave bridge 
frequency, 9.8 GHz; microwave bridge attenuator, 20 dB; modulation frequency, 100 kHz; 





The redox properties of the metallic compounds were probed using cyclic 
voltammetry, refer to Figures 4.11 – 4.12. All the attained cyclic voltammograms (CVs) 
were diffusion controlled at incrementing scan rates, e.g. see the overlay CVs of 1 in 
Figure 4.11 as an example. These CVs are classified as one-electron redox processes as 
their peak current ratios approach one. In addition, all the CVs exhibits quasi-
reversible behaviour since their respective peak to peak separations [∆Ep = 120 mV for 
1 and 90 mV for 2] are different from that of the standard, ferrocene [∆Ep = 80 mV at 
100 mV/s].  
 
The different peak to peak separations of the two complexes are due to the more 
delocalized diimine chelator of 2 which promotes faster electron transfer kinetics in 
comparison to the mono-imine chelator of 1. This phenomenon is further supported 
by the fact that 2 [E½ = 0.32 V vs Ag|AgCl] has a smaller halfwave-potential (E½) 
compared to 1 [E½ = 0.56 V vs Ag|AgCl].  
 
The redox processes as found in the respective CVs are ascribed to the Ru(II)/Ru(III) 
redox couples since they have similar half-wave potentials (E½) as the 
ruthenium(II/III) compounds with Schiff base chelates found in literature. For 
example, nearly equivalent half-wave potentials were observed between the 
paramagnetic ruthenium(III) compound, 1 [E½ = 0.56 V vs Ag|AgCl] and trans-
[RuIII(nbh)(PPh3)2Cl] (H2nbh = N-benzylidene-4-nitrobenzohydrazide) [E½ = 0.58 V vs 





Figure 4.11: Overlay CVs of complex 1 at incrementing scan rates. 
 
 




4.4.3 Crystal Structures 
 
(a) Crystal Structure of 1·2CHCl3 
 
Compound 1 crystallizes in a P21/c space-group along with two chloroform molecules 
of recrystallization, see Figure 4.13. The ruthenium metal atom is at the centre of a 
distorted octahedron which is largely induced by the constrained RuN2C6C7C15 five-
membered chelate ring. Consequently the equatorial bite angle, N2-Ru-C15 [78.6(2)°] 
is considerably smaller than the bond angle formed between cis-chloro [Cl1-Ru-Cl2 = 
88.55(4)°] co-ligands, which are close to octahedral ideality [i.e. 90°]. Furthermore, the 
nearly linear P1-Ru-P2 bond angle of 176.31(4)° is influenced by intramolecular 
interactions between the uncoordinated pyridyl moiety of the pch chelator and 
selected phenyl groups of the triphenylphosphine co-ligands, see Figure 4.14 {I = 3.729 
Å and II = 3.663 Å}. 
 
The difference in the bond lengths of the cis-chloro co-ligands [Ru-Cl1 = 2.452(1) Å 
and Ru-Cl2 = 2.575(1) Å] is due to the variable trans-influence of the N2 and C15 
atoms, respectively.  The bond length of the Ru(III)-NSchiff base bond [2.151(4) Å] is 
similar to the analogous coordination bonds found in other paramagnetic 
ruthenium(III) compounds, [RuCl(bsp)2(PPh3)] [2.119(2) Å and 2.096(2) Å] (Hbsp = N-
(2-hydroxybenzylidene)-benzothiazole) and  trans-[RuCl(bzp)(PPh3)2] [2.069(4) Å] 
(Hbzp =  N-(2-hydroxybenzylidene)-benzimidazole) [18]. In compound 1, the 
ruthenium-carbene bond distance [1.933(5) Å] is shorter than the Ru(III)-Caromatic bond 
distances of trans-[Ru(pnbhMe)(PPh3)2Cl] [2.048(3) Å] (H2pnbhMe = 1-
pyrenaldehyde-4-methyl-benzoylhydrazone) and trans-[RuCl(nabhMe)(PPh3)2] 
(H2nabhMe = 1-naphthaldehyde-4-methyl-benzoylhydrazone) [2.040(6) Å] [22, 23]. 
This is ascribed to the variable steroelectronic properties of the hydrocarbon rings of 
the naphthalene and pyrenyl rings in comparison to the chromone moiety. However, 
the ruthenium-carbene bond distance of 1 is comparable to the organometallic 




Evaluating the intraligand bond distances of the pch chelator; the bond orders of the 
ketonic C8-O2 [1.235(7) Å] and ether C-O [C15-O1 = 1.370(5) Å and C14-O1 = 1.383(6) 
Å] bonds are readily distinguishable. As a result of the formation of the ruthenium-
carbene bond, the C15-C7 bond distance of 1.433(7) Å is not similar to the delocalized 
C-C double bonds within the phenyl ring [e.g. C16-C17 = 1.377(4) Å] but the C15-C7 
bond is still shorter than the C7-C8 [1.455(7) Å] and C8-C9 [1.481(8) Å] single bonds. 
In contrast to the observation of the C15-C17 double bond, the uncoordinated 
analogous bond [1.362(4) Å] of fac-[Re(CO)3(bsch)Cl] (bsch = 2-benzothiazole-4H-
chromen-4-one) were comparable to delocalized C-C double bonds within its 
corresponding chromone phenyl ring [23]. Ruthenium complexes containing 
chromone moieties are rare in the literature. Among the few examples are the 
ruthenium(II) complexes salts, [Ru(bpy)2(MCMIP)]2+ (bpy = bipyridine) and 
[Ru(phen)2(MCMIP)]2+ (phen = phenanthroline ) containing the bidentate neutral 




Figure 4.13: An ORTEP view of complex 1 showing 50 % probability displacement 





Figure 4.14: Demonstration of the intramolecular interactions occurring in complex 1; given 
as I = 3.729 Å and II = 3.663 Å. 
 
(b) Crystal Structure of 2·CHCl3 
 
The triclinic unit cell of 2 contained one molecule of 2 as well as two chloroform 
molecules of recrystallization, see Figure 4.15. The intermolecular interaction (at 3.912 
Å) between the bridging pyridyl rings of respective molecules within each triclinic 
unit-cell allows all the molecules within the crystal lattice to pack in columns parallel 
to the [a]-axis.  The crystal lattice of 2 is stabilized by a series of intramolecular 
interactions between the antipyrine moiety and respective phenyl rings of the 
triphenylphosphine co-ligand, see Figure 4.16 {I = 4.308Å, II= 3.515 Å and III = 3.817 
Å}. Noticeably, the intermolecular interactions I and II differ considerably which 
could potentially be due to the non-classical interactions between one of the 
chloroform molecules of recrystallization and the ketonic O1 atom [O1···· Cl2S = 
3.091(3) Å]. In turn, the nature of the aforementioned intermolecular interaction 




The other coordination sphere bonds of 2 were as expected with a RuII-Npyridyl bond 
length of 1.945(3) Å. As expected, the Ru-P bonds of 2 [2.3155(8) Å] are shorter in 
comparison to the nearly equidistant trans-axial [Ru-P1 = 2.393(1) Å and Ru-P2 = 
2.391(1) Å] bonds of 1 due to the increase in the Lewis acidic character of the latter’s 
ruthenium centre. Octahedral distortion is induced by the constrained equatorial N3-
Ru-N4 [78.4(1)⁰] and N4-Ru-N5 [78.2(1)⁰] bite angles of the bpap chelator. This results 
in the N3-Ru-N5 [156.6(1)⁰] and N4-Ru-Cl1 [174.07(9)⁰] bond angles deviating from 
octahedral ideality. The linear deviation of the axial P-Ru-Cl2 [176.99(3)⁰] bond angle 
is due to the influence of the intramolecular interactions I-III. The hybridization of the 
nitrogens (for 2) is further supported by the Schiff base bond distance [C12-N3 = 
1.313(4) Å and C18-N5 = 1.311(5) Å for 4] which is comparable to other chelating Schiff 
base moieties coordinated to the ruthenium(II) core [25, 26]. However, the effect of 
cyclometallation in 2 causes the C-NSchiff base-C angles [C10-N3-C12 = 115.4(3)⁰ and C18-
N5-C19 = 114.8(3)⁰] to be inconsistent with respect to the expected 120⁰ value. 
 
 
Figure 4.15: An ORTEP view of complex 2 showing 50 % probability displacement 







Figure 4.16: Demonstration of the intramolecular interactions occurring in complex 2; given 



















Table 4.1: Crystal data and structure refinement data. 
 1·2CHCl3 2·CHCl3 
Chemical formula C53H41Cl8N2O2P2Ru C49H44Cl8N7O2PRu 
Formula weight 1184.49 1178.55 
Temperature(K) 100(2) 100(2) 
Crystal system Monoclinic Triclinic 
Space group P21/c P-1 
Unit cell dimensions (Å, °) a = 15.4971(10) a = 13.0192(6) 
 b = 16.9324(12) b = 15.9070(8) 
 c = 20.7864(13) c = 16.3224(8) 
 α = 90 α = 102.418(2) 
 β = 111.254(2) β = 107.355(2) 
 γ = 90 γ = 104.596(2) 
Crystal size (mm) 0.31 x 0.10 x 0.02 0.28 x 0.15 x 0.10 
V(Å3) 5083.42 2964.18 
Z 4 2 




F(000) 2396 1196 
θ range for data collection 
(deg) 
1.41; 26.01 1.39; 26.04 
Index ranges -18 ≤ h ≤ 19 
-20 ≤ k < 20 
-25 ≤ ℓ ≤ 12 
-16 ≤ h ≤ 15 
-19 ≤ k < 19 
-20 ≤ ℓ ≤ 20 




Independent reflections 7974 9986 
Data/Restraints/parameters 7974/0/613 9986/0/617 
Goodness of fit on F2 1.035 1.073 
Observed R, wR2 0.0557; 0.1534 0.0494; 0.1252 
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Chapter 5          S Maikoo 
Chapter 5 
Isolation of Ruthenium Compounds from the 




The upsurge in the medicinal inorganic chemistry of ruthenium emanates from the 
discovery of the potent anti-metastatic cancer activity for NAMI-A, trans-
[RuIIICl4(DMSO)(Im)](ImH) {ImH = imidazole} [1, 2].  Emphasis on using derivatives 
of imidazole has led to the isolation of new candidates for metallopharmaceuticals, 
like trans-[RuIII(Ind)2Cl4][IndH] (KP1019, Ind = indazole) which showed a different 
biodistribution pattern  compared to NAMI-A whereby KP1019 induces apoptosis for 
the treatment of larger tumors [3].  These startling findings has prompted the use of 
benz(imidazole/othiazole) analogues due to their diverse biological activities, see 




X = NH (1H-Benzimidazole)
    = S     (1,3-Benzothiazole)
 
 
Figure 5.1: Structures of Benzothiazole and Benzimidazole. 
 
For example, among the numerous ruthenium compounds with 
benz(imidazole/othiazole) moieties is the arene ruthenium(II) complex, [Ru(η4-
C8H12)(Hpybz)Cl2] (Hpybz = 2-pyridylbenzimidazole)  which exhibited high 




the organometallic ruthenium(II) complex, [(η6-arene)Ru(Hpzbs)Cl]PF6 (Hpzbs = 2-
(1H-pyrazol-5-yl)benzothiazole) exhibited high in vivo anticancer activity towards 
Dalton’s Lymphoma Ascites tumour cells [10]. These profound and diverse biological 
activities of this class of ruthenium complexes are largely owed to their diverse 
coordination environments [11]. Recently, a research study reported the formation of 
benz(imidazole/othiazole) ruthenium(II/III) compounds with diverse structural 
features despite the similar structured ligands [12, 13]. 
 
In this chapter, the isolation of novel ruthenium compounds from the analogous 
chelating behaviour of 2-hydroxyphenylbenz(imidazole/othiazole) ligands, 2-
hydroxyphenyl-1H-benzimidazole (Hobz) and 2-hydroxyphenyl-1H-benzothiazole 
(Hobs), are reported (see Figure 5.2). As a result, the diamagnetic ruthenium(II) 
complex salt, [RuCl(Hobz)2(PPh3)]Cl (1) and paramagnetic ruthenium complex, 
[RuIIICl(obs)2(PPh3)] (2) were formed. Although both heterocyclic chelators have 
similar structures and analogous chelating behaviour (viz. N,O bidentate moieties), 
the Hobz chelators in 1 coordinated as a neutral bidentate N,O moeities while each 
obs ligand in 2 acted as a monoanionic bidentate N,O moiety resulting in ligand-





X = NH (Hobz)
    = S (Hobs)
 
 
Figure 5.2: Generic structure of the heterocyclic ligands: 2-hydroxyphenyl-1H-









5.2.1 Synthesis of [RuCl(Hobz)2(PPh3)]Cl (1) 
A two molar ratio of Hobz (0.044 g, 0.208 mmol) was added to a one molar ratio of 
trans-[RuCl2(PPh3)3] (0.100 g, 0.104 mmol) in 20 cm3 ethanol. The resultant reaction 
mixture was then heated until reflux for 4 hours and then filtered. XRD quality dark 
green cubic crystals were grown over several days from the slow evaporation of the 
mother liquor. Yield = 78 % based on Ru, m.p. = 334.5 - 335 °C.  IR (νmax/cm-1): ν(O-H) 
3424 (m), ν(N-H) 3057 (m), ν(C=N) 1477, 1431 (s), ν[Ru-(PPh3)] 692 (vs). 1H NMR 
(295K/d2-CD2Cl2/ ppm): 7.78 (br, s, 1H, N2H; N4H), 7.69 – 7.52 (m, 15H, PPh3), 7.50 – 
7.38 (m, 8H, H2, H3, H4, H5, H15, H16, H17, H18), 7.28 – 7.20 (m, 8H, H9, H10, H11, 
H12, H22, H23, H24, H25), 5.79 (br, s, 2H, O1H, O2H); 31P NMR (295K/ d2-
CD2Cl2/ppm): 27.93. UV-Vis (DMF, λmax (ε, M-1cm-1)): 224 nm (2129); 254 nm (17063); 
277 nm (sh, 12614); 291 nm (16537); 299 nm (16539); 346 nm (11174); 484 (16706); 709 
nm (2129). Conductivity (DCM, 10-3 M): 172.89 ohm-1 cm-2 mol-1. 
 
5.2.2 Synthesis of [RuIIICl(obs)2(PPh3)] (2) 
A 1:2 molar ratio reaction between trans-[RuCl2(PPh3)3] (0.100 g, 0.104 mmol) and 
Hobs (0.047 g, 0.208 mmol) conducted in 20 cm3 methanol at reflux temperature for 4 
hours. Afterwards, the mother liquor was allowed to cool to room temperature, 
filtered and after several days of slow evaporation, blue cubic crystals were grown 
which were suitable for X-ray analysis. Yield = 75 % based on Ru, m.p. = 234.7 – 235.9 
°C.  IR (νmax/cm-1): ν(C=N) 1482, 1433 (s), ν[Ru-(PPh3)] 692 (vs). UV-Vis (DMF, λmax (ε, 
M-1cm-1)): 254 nm (9795); 262 nm (10287); 293 nm (20072); 302 nm (sh, 17037); 317 nm 










5.3 X-Ray Crystallography 
 
The X-ray data for both the metal complexes were recorded on a Bruker Apex Duo 
equipped with an Oxford Instruments Cryojet and an Incoatec microsource operating 
at 30 W power and 100(2) K. The data was reduced with the programme SAINT [14] 
and solved by direct methods using the SHELXS-97 [15] and WINGX [16] 
programmes. All non-hydrogen atoms were located in the difference density map and 
refined anisotropically with SHELXL-97 [15]. All hydrogen atoms were included as 
idealised contributors in the least squares process. Their positions were calculated 
using a standard riding model with C-Haromatic distances of 0.93 Å and Uiso = 1.2 Ueq.  
The benzimidazole N-H bond of the Hobz ligands for compound 1 were located in the 
difference density map and refined isotropically. 
 
5.4 Computational Details 
 
Computational calculations were conducted with the Gaussian 09W software package 
[17]. The geometries of 1 and 2 were optimized at the DFT level using the B3LYP 
functional and the LANL2DZ basis set [18, 19, 20]. Prior to the calculation on 
compound 1, the counterion was removed and the resultant structure was used as the 
starting conformer. Good agreement was found between the optimized and 
geometrical parameters (refer to Tables 5.4–5.6) with the minor deviations due to the 
fact that gas phase optimized structures does not account for non-classical hydrogen 












5.5 Results and Discussion 
 
5.5.1 Synthesis, Spectroscopic Characterization and Computational Studies 
 
The ruthenium compounds, [RuCl(Hobz)2(PPh3)]Cl (1) and [RuIIICl(obs)2(PPh3)] (2) 
were isolated from the 1:2 molar reactions of trans-[RuCl2(PPh3)2] with 2-
hydroxyphenylbenzimidazole (Hobz) and 2-hydroxyphenylbenzothiazole (Hobs), 
respectively. The neutral (for 1) and monoanionic (for 2) N,O-donor bidentate moieties 
coordinates in a ‘2+2’ manner while the remaining coordination sites are occupied by 
the triphenylphosphine and chloride co-ligands (see Figure 5.3). The high isolation 
yields of metallic compounds in its crystalline form indicate that the major products 
were isolated. Furthermore, despite the similar skeletal structures of the free 
heterocyclic ligands, the aforementioned’s different stereoelectronic properties are 
emphasized by the formation of diamagnetic ruthenium(II) and a paramagnetic 
ruthenium(III) compounds, respectively. The dark green and blue crystals of the 
complexes are insoluble in alcoholic media but readily dissolve in chlorinated solvents 
as well as high boiling point aprotic solvents including dimethylformamide and 
dimethylsulfoxide. The high molar conductivity value of 1 affirms that it is a 1:1 













The 1H NMR spectral analysis of the diamagnetic complex 1 (see Figure 5.5) showed 
that the aromatic signals proton signals of Hobz chelators coalesced into two 
multiplets (at 7.50 – 7.38 ppm and 7.28 – 7.20 ppm) which occurred originally as a 
doublet, two triplets and two multiplets within the proton spectrum of the free-ligand. 
The broad singlets of the benzimidazole moieties (7.78 ppm) for 1 are found more up-
field with respect to its aromatic protons while the phenolic protons resonate more 
down-field at 5.79 ppm. These signals are also shifted upon coordination as they were 
originally found at 13.20 ppm and 5.41 ppm within the proton spectrum of the free 
ligand. 31P NMR spectroscopy confirmed the presence of the phosphorous atoms in 1 
(see Figure 5.6). 
 
 






Figure 5.5: 1H NMR spectrum of compound 1 in the range of 7.18 and 7.86 ppm. 
 
 





Coordination of the heterocyclic chelators is confirmed by the ν(C=N) bands (1477 cm-
1, 1431 cm-1 for 1 and 1482 cm-1, 1433 cm-1 for 2) vibrating at lower frequencies compare 
to that of the free ligands (1607 cm-1, 1593 cm-1 for Hobz and 1620 cm-1, 1584 cm-1 for 
Hobs) (see Figures 5.7 and 5.8). This finding is also supported by the absence of the 
hydroxyl vibrational band in 2 which affirms the obs chelators coordinate as 
monoanionic moieties. In contrast, the ν(O-H) and ν(N-H) of the neutral Hobz ligand 
of 2, appears as two medium-intensity bands at 3424 cm-1 and 3057 cm-1, respectively. 
Another distinctive feature of the IR spectra for the metallic compounds, is the ν[Ru-











Figure 5.8: Overlay IR spectra of the free-ligand, Hobs and complex 1 between 1750 and 650 
cm-1. 
 
Predominately all the intraligand π-π* transitions of the free ligands are consolidated 
at similar wavelengths in the electronic spectra of 1 (below 400 nm) and 2 (below 330 
nm) (see Figures 5.9 and 5.10). However in complex 2, an intraligand π-π* transition 
at 351 nm is observed at more blue-shifting regions in comparison to the transition 
band observed at 372 nm within the UV-Vis spectrum of its free-ligand. Furthermore, 
the UV-Vis spectrum of 1 showed a Metal-to-Ligand-Charge-Transfer (MLCT) band 
and a metal-based d-d transition which occurs at 484 nm and 709 nm, respectively with 
lower extinction coefficients compared to 2. The absence of the d-d transition for the 
paramagnetic d5 complex 2 can be explained by the higher computed band-gap energy 
of the latter in comparison to the complex cation 1 since compound 1 showed a metal-
based transition (at 709 nm) experimentally although it is low-spin d6-system. Another 
contributive factor is that the high electron density of the obs chelators (in 2) observed 








Figure 5.9: Overlay UV/Vis spectra of complex 1 and its ligand, Hobz. 
 




Evaluating the optimized structures of the complex cation 1 and complex 2 (see Table 
5.1) indicates that the complex cation 1 is energetically more favourable with an 
energy of -5.948 x 104 eV compared to complex 2 calculated with a total energy of -
5.689 x 104 eV. This is also apparent from the lower band-gap energy of 3.189 eV 
computed for the complex cation of 1. In complex 2, the main contributions from the 
frontier orbitals of the heterocyclic chelators are observed within the Highest 
Occupied Molecular Orbital (HOMO) configuration. The corresponding frontier 
orbitals of compound 1 are virtually non-existent in the HOMO configuration while 
the electron density resides on one heterocyclic chelator in the Lowest Unoccupied 
Molecular Orbitals (LUMO) configurations of both metallic compounds 1 and 2. In 
addition, the HOMO configurations of the optimized structures are also re-enforced 
by contributions from 2pz and dyz orbitals originating from the chloride co-ligand as 
well as from the metal atom, respectively.  
 
Table 5.1: The DFT parameters of the complex cation of 1 and complex 2 where the energies 
is given in electron volts (eV). 
 Complex cation of 1 Complex 2 
Total Energy -5.938 x 104 -5.689 x 104 
HOMO   
LUMO 
  
HOMO Energy -7.523 -5.323 
LUMO Energy -4.334 -2.087 





ESR spectra of 2 (see Figures 5.11-5.13) were obtained both in the solid state and in 
dichloromethane at low and room temperatures, refer to Table 5.2. As expected, the 
influence of the ‘2+2’ coordination modes of the bidentate obs chelators, affords 
distorted rhombic ESR spectra in the solid state with comparable g-values and these 
values were found to be similar to other low-spin d5 ruthenium compounds within 
distorted octahedral geometries [12]. A classical isotropic singlet (g-value = 2.116) was 
attained for the liquid sample (at 298 K) but the frozen liquid sample (at 77 K) showed 
three distinctive signals owing to slower spin-lattice relaxation rates of the latter. In 
addition, the larger hyperfine coupling constants of the liquid samples in comparison 
to that of the solid samples indicates that the spin relaxation life-time of the frozen 
samples were longer. The low temperature ESR parameters of 2 in dichloromethane 
were similar to what was obtained for the diimine ruthenium(III) complex, 
[Ru(naphprop)Cl(CO)]; H2naphprop = bis-(napthaldehyde)propylenediimine in DMF 
at 77 K [22]. 
 
 






Figure 5.12: Solid state ESR spectrum of complex 2 at 77 K. 
 
 





Table 5.2: ESR spectral analysis of complex 2 at room (denoted as A) and low temperatures 
(denoted as B). 
Sample State of 
sample 
gx gy gz giso 
298 K Solid 2.267 2.082 1.973 - 
Liquid - - - 2.116 
77 K Solid 2.264 2.0779 1.938 - 




The voltammetric studies of the metallic compounds 1 and 2 showed single reductive 
redox processes ascribed to the Ru(I/II) and Ru(II/III) redox couple, respectively, see 
Figure 5.14.  These redox couples exhibits both diffusion controlled behaviour at 
incrementing scan rates, see Figures 5.15 and 5.16.  In addition, peak current ratios 
approaching one were observed for the respective redox couples which is reminiscent 
of one electron redox processes.  The redox couple of compound 1 is classified as 
reversible since the peak to peak separation [ΔE(1) = 90 mV]  is the same as the 
standard, ferrocene (ΔE = 90 mV). Contrastingly, the peak to peak separation of 
compound 2 [ΔE = 80 mV] is smaller than that of ferrocene which is indicative that the 
redox couple is quasi-reversible. In addition, the smaller peak to peak separation of 
compound 1 indicates that it has faster electron transfer kinetics when compared to 
compound 1 and the standard, ferrocene. These halfwave potentials (E½) were similar 
to other ruthenium(II/III) complexes found within literature e.g. trans-
[RuCl(bzp)(PPh3)2] Hbzp = N-(2-hydroxybenzylidene)-benzimidazole) and the 
diamagnetic ruthenium complex, trans-[Ru(L)(CO)(PPh3)2] (H2L = 4-
bromobenzoylhydrazone)  with halfwave potentials of 0.70 V and –0.81 V, 







Figure 5.14:  Overlay cyclic voltammograms (CVs) of compound 1 (at 300 mV/s), 
compound 2 (at 300 mV/s) and the standard, ferrocene (at 100 mV/s). 
 
 






Figure 5.16: Overlay CVs of complex 2 at incrementing scan rates. 
 
 
5.5.3 Crystal Structures 
 
The mononuclear 1 and 2 compounds crystallize in P21/n space-groups whereby their 
respective monoclinic unit-cells occupy four molecules each. Furthermore, the crystal 
lattice of 1 is stabilized by classical hydrogen-bonding interactions between the 
chloride counterions and the benzimidazole N-H groups of adjacent molecules 
[NH···Cl = 2.47(3) Å]. In addition, further stabilization is afforded by the interaction 
between co-planar benzimidazole moieties (interplanar spacings of 3.594 Å) which are 
above the distance for classical π-π-stacking interactions at 3.5 Å. Both the metallic 
compounds exhibits distorted octahedrons given by the O1-Ru-O2 (177.12(7)⁰ for 1 
and 177.98(6)⁰ for 2), N3-Ru-P (173.65(5)⁰ for 1 and 174.18(5)⁰ for 2) and N1-Ru-Cl1 
(172.40(5)⁰ for 1 and 173.40(6)⁰ for 2) angles deviating from linearity. The non-ideal 
octahedral angles are accounted to the constrained O1-Ru-N1 (86.11(7)⁰ for 1 and 




affords the RuO1C1C6C7N1 and RuO2C14C19C20N2 6-membered chelate rings (see 
Figures 5.17 and 5.18). 
 
As expected, the Ru-N/O coordination bonds of 1 (Ru-N1 = 2.049(2) Å, Ru-N2 = 
2.090(2) Å, Ru-O1 = 1.951(2) Å and Ru-O2 = 1.960(2) Å) is shorter than the 
corresponding bonds of 2 (Ru-N1 = 2.079(2) Å, Ru-N2 = 2.139(2) Å, Ru-O1 = 1.984(1) 
Å and Ru-O2 = 2.003(1) Å) which is ascribed to the higher Lewis character of the 
ruthenium centre in 2. In contrast, the longer Ru-P and Ru-Cl bond lengths of 1 (Ru-P 
= 2.3811(8) Å and Ru-Cl = 2.4049(7) Å) in comparison to 2 (Ru-P = 2.3437(7) Å and Ru-
Cl = 2.3783(6) Å), emanates from the variable stereoelectronic properties of the trans-
positioned benzimidazole (for 1) and benzothiazole (for 2) moieties. Also noticeably, 
the Ru-N bond distances of 1 and 2 are different due to the difference in trans-influence 
imposed on these coordinated nitrogen atoms.  
Surprisingly, the ruthenium atom attached to the deprotonated phenolic oxygen bond 
distances of 2 was different despite the fact that they are in trans-axial positions. 
However, the Ru-O coordination sphere bond lengths of 1 were similar to coordinated 
phenolic oxygen bonds found within stereoisomers of 
[Ru(tolylterpy)(Hpb)(H2O)]PF6, tolylterpy = 4’-(4-methylphenyl)-2,2’:6’,2”-
terpyridine, Hpb = 2-hydroxyphenylbenzoxazole with bond distances of 1.9534(18) Å 
(for the cis-stereoisomer) and 1.9623(6) Å (for the trans-stereoisomer) [24]. The same 
applied to the RuIII-O bond distances of 2 which were comparable to analogous bonds 
found in the paramagnetic Schiff base ruthenium complexes, 
[Ru(HahsH)(PPh3)2Cl2].2CH2Cl2 [Ru-O = 2.023(3) Å] and [Ru(ahsH)(PPh3)2Cl2] [Ru-O 
= 2.028(4) Å], H2ahsH = N-acetyl-N’-(salicylidene)hydrazide [25]. The other 
coordination sphere bond distances of 1 and 2 were also within range as the 
corresponding bonds found within literature for ruthenium(II/III) complexes 
containing  benzimidazole or benzothiazole moieties. Like in the case of where the 2-
carboylatebenzimidazole (ocbz) ligands coordinate in a ‘2+2’ fashion as monoanionic 
N,O-bidentate chelators in the ruthenium(II) complex, cis-[Ru(ocbz)2(PPh3)2] with Ru-





The C=N bonds (C7-N1 = 1.329(2) Å and C20-N3 = 1.335(2) Å) of compound 1 are 
readily distinguishable from its C7/20-N bonds (C7-N2 = 1.357(3) Å and C20-N4 = 
1.355(3) Å) but the similar to the C=N bonds (C7-N1 = 1.325(3) Å and C20-N2 = 
1.311(3) Å)   found within complex 2 affirming their bond orders.  Furthermore, the 
intraligand C-S (S1-C7 = 1.728(3) Å, S1-C8 = 1.730(3) Å, S2-C20 = 1.735(2) Å and S2-
C21 = 1.733(2) Å) bond distances were nearly equidistant showing that the bond 
orders are one. 
 
 
Figure 5.17:  An ORTEP view of compound 1 showing 50 % probability displacement 






Figure 5.18: An ORTEP view of complex 2 showing 50 % probability displacement 

















Table 5.3: Crystal data and structure refinement data. 
 1 2 
Chemical formula C44H35Cl2N4O2PRu C44H31ClN2O2PRuS2 
Formula weight 854.70 851.32 
Temperature (K) 100(2) 296(2) 
Crystal system Monoclinic Monoclinic 
Space group P21/n P21/n 
Unit cell dimensions (Å, °) a = 15.647(5) a = 12.4367(5) 
 b = 14.519(5) b = 22.1300(9) 
 c = 18.313(5) c = 13.4062(5) 
 α = 90.000(5) α = 90.00 
 β = 102.540(5) β = 94.377(2) 
 γ = 90.000(5) γ = 90.00 
Crystal size (mm) 0.24 x 0.11 x 0.09 0.21 x 0.17 x 0.09 
V(Å3) 4061.08 3678.95 
Z 4 4 
Density (calc.) (Mg/m3) 1.398 1.537 
Absorption coefficient (mm-1) 0.599 0.698 
F(000) 1744 1732 
θ range for data collection (deg) 1.55; 26.07 1.78; 26.05 
Index ranges -19 ≤ h ≤ 19 
-17 ≤ k < 17 
-22 ≤ ℓ ≤ 22 
-15 ≤ h ≤ 15 
-27 ≤ k < 25 
-16 ≤ ℓ ≤ 14 
Reflections measured 35293 31756 
Observed reflections [I>2σ(I)] 8028 7165 
Independent reflections 7104 6012 
Data/Restraints/parameters 7104/0/503 6012/0/478 
Goodness of fit on F2 1.057 1.026 
Observed R, wR2  0.0290; 0.0733 0.0288; 0.0618 











Table 5.4: Selected bond lengths [Å] and bond angles [°] for 1. 
 Experimental  Optimized 
Ru-N1 2.049(2) 2.0880 
Ru-N2 2.090(2) 2.1077 
Ru-O1 1.951(2) 2.1103 
Ru-O2 1.960(2) 2.1750 
Ru-P 2.3811(8) 2.5119 
Ru-Cl 2.4049(7) 2.5096 
N1-C7 1.329(2) 1.3525 
N2-C7 1.357(2) 1.3885 
N3-C20 1.335(2) 1.3492 
N4-C20 1.355(3) 1.3867 
O1-Ru-O2 177.12(7) 173.63 
N3-Ru-P 173.65(5) 173.74 
N1-Ru-Cl1 172.40(5) 167.73 
O1-Ru-N1 86.11(7) 86.23 


















Table 5.6: Selected bond lengths [Å] and bond angles [°] for 2. 
 Experimental  Optimized 
Ru-N1 2.079(2) 2.1470 
Ru-N2 2.139(2) 2.1454 
Ru-O1 1.984(1) 2.0282 
Ru-O2 2.003(1) 2.0811 
Ru-P 2.3437(7) 2.5250 
Ru-Cl 2.3783(6) 2.4675 
N1-C7 1.325(3) 1.3384 
N2-C20 1.311(3) 1.3345 
S1-C7 1.728(3) 1.8347 
S1-C8 1.730(3) 1.8002 
S2-C20 1.735(2) 1.8365 
S2-C21 1.733(2) 1.8013 
O1-Ru-O2 177.98(6) 175.56 
N3-Ru-P 174.18(5) 171.03 
N1-Ru-Cl1 173.40(16) 173.21 
O1-Ru-N1 87.31(7) 86.92 
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Chapter 6          S Maikoo 
Chapter 6 
Conclusion and Future Work 
The foremost objectives of this research study were achieved in terms of the design, 
synthesis and characterization of novel ruthenium complexes with multidentate N-
donor ligands. In all the formulated ruthenium compounds, the metal centres are 
stabilized by various multidentate N-donor ligands, e.g. by Schiff base bearings 
various biologically significant components including uracil (see Chapter 3), 
antipyrine or chromone moieties (see Chapter 4).  Likewise in chapter 5, the analogous 
chelating behaviour of 2-hydroxyphenylbenz(othiazole/imidazole) chelators resulted 
in the  characteristic octahedral geometries. Single crystal X-ray analysis of the 
resultant complexes also revealed that the mono-imine chelators coordinated to the 
trans-[RuII/III(PPh3)2] cores while the highly delocalized diimine and the ‘2+2’ 
heterocyclic chelators replaced two bulky PPh3 co-ligands of the metal precursor. The 
distinctive difference in the structural features of the mono-imine and diimine 
ruthenium compounds are also reflected in their attained electrochemical properties. 
 
Future work entails exploring the anticancer and antimalarial activities of the 
formulated ruthenium compounds. Prior to evaluating the anticancer activities of the 
diimine and ‘2+2’ heterocyclic ruthenium compounds, DNA binding capabilities of 
the aforementioned metallic compounds will be investigated towards calf thymus 
(CT)-DNA with the aid of UV/Vis spectroscopy. The prevalence of the bulky trans-
axial triphenylphosphine co-ligands is clearly problematic for designing potentially 
new ruthenium anticancer agents. Ruthenium compounds with the bulky trans-
[Ru(PPh3)2] core will not be able to intercalate between the DNA base pairs of the CT-
DNA and thus the antimalarial studies will be conducted on these metallic 
compounds. To combat this design flaw, the ligands used in this study and proposed 
in the future work will be reacted with the metal precursor, (cymene)ruthenium 
dichloride dimer (see Figure 6.1) since as emphasized in Chapter 1, arene 












Figure 6.1: Structure of the (cymene)ruthenium dichloride dimer. 
 
The scope of this study will be broadened to include the bis-heterocyclic ligands (see 
Figure 6.2) containing the benzothiazole and benzimidazole moieties used in Chapter 
5. This should afford an interesting comparative study between the coordination 
modes as well as the biological activities of the mono- and bis-heterocyclic ruthenium 
compounds. The motivation for using these ligands arises from their ability to 
coordinate to a vast number of transition metals, as emphasized by their high 
coordination affinity to the iron(II) and rhenium(V) metal centres [1]. Furthermore, 
the reduction of the Schiff bases to their corresponding amines may eliminate 





X = O,S or NH









Finally, not only has this research study produced an improved understanding and 
new knowledge of the coordination chemistry of ruthenium with biologically relevant 
Schiff base chelates, but it has also afforded impetus for the development of new 
ruthenium complexes for therapeutic applications.  
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